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Presently, approximately one-third of all biopharmaceutical drugs are derived 
from biological sources like gram-negative bacteria. Gram-negative bacteria like E.coli 
are much cheaper to cultivate and provide higher biotherapeutic yield compared to 
mammalian cells. On extracting the useful biotherapeutics from the gram-negative 
bacterial cells (E.coli), endotoxin present in the bacteria is released in the surrounding 
media thus contaminating the lifesaving biotherapeutics. Application of the endotoxin-
contaminated therapeutics to humans or animals can cause serious health issues like 
septic shock, tissue injury and ultimately death. Hence, thorough purification of 
biotherapeutics before parenteral application is necessary. Although there are multiple 
methods for removing endotoxins, but achieving high protein recovery and purification 
efficiency are still a challenge. 
We have demonstrated a cost-effective technology using a biocompatible polymer 
nanoparticle of approximately 800 nm diameter. The polymeric nanoparticle removed 
>99% endotoxins from water, phosphate buffer saline (PBS) and protein solutions 
including monoclonal antibodies (MAb). It also showed a high protein recovery of ~99 
%. Additionally, the polymeric nanoparticle was capable of being reused multiple times 
after being regenerated. Further, to enhance the throughput, flow properties and to scale 
up the whole system, the polymeric nanoparticles were incorporated in a portable and flat 
sheet biofilter. The biofilter is effective in removing >99% endotoxins from water and 
protein solutions with a protein recovery of > 90%. Finally, the whole filtration set-up 
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1. INTRODUCTION  
1.1. BACKGROUND 
Pharmaceutical manufacturing deals with selection and optimization of the cell 
source, media composition and physico-chemical bioreactor operating conditions to 
maximize the culture yield and productivity (Figure 1.1) 1-3. Escherichia coli is a cost 
effective and attractive choice for producing therapeutic monoclonal antibodies, 
recombinant proteins and other biopharmaceuticals due to their rapid growth, minimal 
nutritional requirements, high product yield and transformation capability 4-11. With the 
millions of strains of bacteria, and gene-altering technology steadily improving, the 
possibilities are endless 12. One of the most recognizable products derived from 
genetically engineered E. coli is the hormone insulin. Before being manufactured by 
bacteria, insulin was originally extracted from dogs and later pigs that was an extremely 
inefficient process, making the product rare and expensive 13. The advent of E. coli -
produced insulin such as recombinant human insulin (Humulin) drastically increased its 
availability for diabetics 14. However, biopharmaceutical products manufactured using 
E. coli or other gram-negative bacteria are subject to endotoxin contamination 15-21.  
Endotoxins are present in the outer cell wall of gram-negative bacteria that 
contribute to the organization and stability of the membrane 16-22. Endotoxin consists of 
three regions: a core polysaccharide, a long chain polysaccharide, and a non-polar lipid 
called Lipid A (Figure 1.2) 20,23. The core polysaccharide has an outer hexose region and 
an inner heptose region and the long chain polysaccharide is a strain-specific surface 
antigen (O-antigen) that consists of repeating oligosaccharide subunits 17,20. The core 
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polysaccharide and the O-antigen are both hydrophilic while Lipid A is hydrophobic. The 
toxicity of endotoxin is associated with Lipid A 24-26. Lipid A triggers the production of 
pro inflammatory cytokines 27,28 and activation of the coagulation cascade 20,29 which can 
lead to sepsis and septic shock 30-34 . A pyrogenic reaction can be caused by as little as 1 
ng of endotoxin per kilogram of body weight per hour 16-21,35. The standard unit for 
endotoxin measurements is an endotoxin unit (EU), which is equal to the activity of 0.1 
ng of E. coli endotoxin 36,37. For intravenous applications, a maximum of 5 EU per 
kilogram of body weight can be administered to a patient per hour 36,38,39, but acceptable 
concentrations in biopharmaceutical products vary depending on the required dose 40,41.  
Endotoxin is highly stable and is resistant to destruction by heat or pH 25,39,42. 
Additionally, endotoxins may form stable interactions with target therapeutic compounds 
that further complicates separations 23,43,44. Downstream processing of recombinant 
protein products accounts for approximately 45-92% of the total manufacturing costs 
10,45,46. In addition to the downstream processing, the detection of endotoxins is absolutely 
critical for the safety of patients across the globe who rely on the purity of treatments 
prescribed  28. The purpose of this review is to discuss these aspects of an array of 
endotoxin detection and removal technologies.  
1.2. BIOLOGICAL ENDOTOXIN DETECTION TECHNIQUES 
Biological detection techniques include rabbit pyrogen test (RPT), limulus 
amebocyte lysate (LAL) assay and bovine whole blood assay (bWBA) that use natural 




Figure 1.1. A simplified scheme of biopharmaceutical production, separation and 
purification steps. Biopharmaceutical manufacturing is divided into two areas: upstream 
fermentation or cell culture and downstream purification processes. Each area contains 
multiple unit operations. The primary downstream unit operation is chromatography that 
includes variations in modes such as affinity, cation-exchange, anion-exchange, ceramic 
hydroxyapatite, and hydrophobic-interaction chromatography. The process performance 
is mainly determined by the rate of molecule transport to the binding sites. In large 
chromatographic columns, small adsorbent particles provide high surface area for binding 
but generate a large pressure drop at high fluid velocity. On the other hand, large 
adsorbent particles minimize active binding site per volume as well as reduce mass 
transport. (Figure reproduced with permission from Jozala et. al., Ref. 3). 
 
 
Figure 1.2. Schematic view of the chemical structures of endotoxin from E.coli and 
properties of endotoxin binding materials.(a) Schematic view of the chemical structure of 
endotoxin from E. coli. Endotoxins are lipopolysaccharides that consist of a 
heteropolysaccharide (O-antigen), the core oligosaccharide, and a non-polar lipid A tail. 
(b) Endotoxins form aggregates in micelle, cube, lamellar or vesicle forms exhibiting a 
net negative charge in pharmaceutical solutions. The negatively charged “micellar” 
endotoxins can be adsorbed on polycationic ligands, or the individual endotoxin 




out by newer, more accurate testing methods such as biosensors that are described after 
the biological detection techniques. 
1.2.1. Rabbit Pyrogen Test (RPT). The oldest and simplest of the endotoxin 
detection techniques, RPT involves injecting the biological sample in question into live 
rabbits and waiting for a fever to develop 23,47. This method works on the principle that 
rabbits and humans share similar fever patterns under influence of endotoxins. It was 
determined that a temperature increase of 0.5°C over a time span of 180 min after 
injection constituted a fever 48. It was also found that it has a detection limit of 
approximately 0.5 EU/ml (endotoxin unit/milliliter) or around 0.05 ng of endotoxin/ml of 
solution 49. As rudimentary as the technique seems, a detection rate as low as 0.1 ng was 
considered very accurate at the time of this methods development in 1912. This technique 
has been praised for its accuracy; being an in vivo technique, it is easy to accept the 
results of the test as researchers can physically see the test subject show symptoms of 
infection. Seeing the test subject suffering the effects of endotoxins provides a 
compelling argument to the presence of endotoxins in the sample. This method is often 
criticized 50. The scientific world is generally moving away from live test subjects where 
avoidable, in particular, animal testing. While this test was once considered the best in 
the industry, and is still being performed in parts of Japan, today it is criticized for its 
need for many samples, and its near-obsolete sensitivity and accuracy compared to other 
methods 51. 
1.2.2. Limulus Amebocyte Lysate (LAL) Assay. Unlike RPT, LAL assay 
developed in the 1960s does not involve live test subjects. It does, however, rely on an 
extract from the blood of the Limulus polyphemus species of horseshoe crab 52,53. The 
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extract is used in one of three ways. First and simplest, the gel-clot. This test involves 
mixing equal parts of extract and sample. If a gel has formed and the mixture remains 
intact in the bottom of the tube, the test shows positive 54. This means the sample has at 
least enough endotoxins to trigger a positive reaction, the limit of this being around the 
range of 0.03 EU/mL to 0.06 EU/ml. The other two methods are turbidimetric and 
chromogenic methods. Both are referred to as photometric tests as they require an optical 
reader for analysis. The chromogenic assay is performed by replacing a natural substrate, 
coagulen, with a chromogenic, or colored one. The chromogenic substrate is cleaved by 
an endotoxin-activated enzyme coagulase, and the chromogenic molecule is released 
from the substrate into the suspension measured by spectrophotometry 55. The 
turbidimetric method is similar to the chromogenic method, but instead measures the 
turbidity of the solution 56. The rate of turbidity and absorbance (color change) are 
proportional to the endotoxin concentration. All three tests rely on the same protein, 
Factor C coagulation cascade found in horseshoe crabs’ blood (Figure 3c). The endotoxin 
activates Factor C which goes onto activate Factor B following the formation of a clotting 
enzyme 57,58. In gel clot and turbidity assays, the clotting enzyme transforms coagulen 
into coagulin, creating the gel in the gel clot test, as well as the clouding agent in the 
turbidity test. The chromogenic method follows the same pathway, but instead of using 
coagulen, it uses a complex of amino acids and p-nitroaniline (pNA), as the chromogenic 
factor. The enzyme trims the pNA off of the complex, turning the suspension a yellow 
color. This color is too faint to discern by the naked eye so a spectrometer must be used 
23. These tests are widely accepted as the official endotoxin test in the pharmaceutical 
community 59. Every drug and medical device that is tested by the US Food and Drug 
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Administration (FDA) must undergo and pass a LAL test 60,61. As previously mentioned, 
this method is much more accurate than RPT, particularly the photometric methods. This 
method still has its drawbacks. LAL assay gives both false negative and false positive 
results by the presence of test interferences. False negative results are observed when 
endotoxins are masked by product formulation matrices such as surfactants (e.g., 
polysorbate 20, polysorbate 80 etc.), buffer constituents (e.g., citrate, phosphate etc.) and 
cell culture medium, or by aggregation with products 62-64.  As a result, endotoxin is not 
accessible to react with LAL reagents, a phenomenon well known as low endotoxin 
recovery (LER) 65.  In contrast, LAL assay also produces a falsely higher reading by the 
presence of (1→3)-ß-D-glucans, a major cell membrane component that cause a false 
positive reaction triggering the protease enzyme Factor G pathway and form the same 
coagulin protein end product as found in LAL reactions 66,67. The LAL test is challenging 
for measuring endotoxin activity in proteins, peptides and polymers because the active 
site of endotoxin binds with the products neutralizing the biological activity of 
endotoxins 68-71. The protein cascades the LAL assay relies on is disrupted in samples 
with free metal ions, and similar to RPT, the method is subject to the same public outcry 
for its treatment of horseshoe crabs. While the phlebotomy itself is not fatal, an 
approximated 20% of the crabs fail to survive after being returned to sea 23. Following the 
discovery of Factor C as endotoxin-activated portion of the protein cascade, attempts 
have been made to replace the conventional LAL test, with one using recombinant Factor 
C 72. As technology improves, alternative techniques are being developed to ease the 






Figure 1.3. Endotoxin detection mechanism using LAL assay. (a) Endotoxin induced 
defense mechanisms in circulating hemolymphs of horseshoe crabs. The LAL assay is 
designed based on the immunogenic reactions developed in the blood of horseshoe 
crabs. Upon exposure to endotoxins, the electron dense large granules (L-granule) and 
less electron dense small granular (S-granule) amebocytes become activated by 
zymogen factor C. (b) Coagulation cascade in horseshoe crab blood. Endotoxin 
activates plasma membrane-bound factor C. Factor C is a single chain glycoprotein 
(M.W. = 123 kDa) comprising of a heavy chain (M.W. = 80 kDa) and light chain 
(M.W. = 43 kDa) that plays a major key role as an activator to immune system. Upon 
binding with endotoxins, an autocatalytic activity triggers with the cleavage of Phe–Ile 
bond resulting in an activated factor C that interacts with factor B converting it into a 
clotting enzyme. Clotting enzyme cleaves coagulogen at two terminal of peptide C at 
the Arg–Lys and Arg–Gly forming insoluble coagulin gel. (c) The proteolytic activity 
feature of the activated clotting enzyme in horseshoe crab’s blood is used on synthetic 
chromogenic i.e. Gly–Arg–p-nitroaniline substrates instead of coagulogen to detect 
endotoxin as it separates p-Nitroaniline (p-NA). Upon addition of a chromogenic 
substrate, Ac-Ile-Glu-Ala-Arg-pNA, the activated protease, clotting enzyme catalyzes 
the release of p-nitroaniline (pNA), resulting in a yellow color that can be quantitated 
by measuring the absorbance at 405 nm (or absorbance at 340 nm) and extrapolating to 
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Figure 1.3. Endotoxin detection mechanism using LAL assay. (a) Endotoxin induced 
defense mechanisms in circulating hemolymphs of horseshoe crabs. The LAL assay is 
designed based on the immunogenic reactions developed in the blood of horseshoe crabs. 
Upon exposure to endotoxins, the electron dense large granules (L-granule) and less 
electron dense small granular (S-granule) amebocytes become activated by zymogen 
factor C. (b) Coagulation cascade in horseshoe crab blood. Endotoxin activates plasma 
membrane-bound factor C. Factor C is a single chain glycoprotein (M.W. = 123 kDa) 
comprising of a heavy chain (M.W. = 80 kDa) and light chain (M.W. = 43 kDa) that 
plays a major key role as an activator to immune system. Upon binding with endotoxins, 
an autocatalytic activity triggers with the cleavage of Phe–Ile bond resulting in an 
activated factor C that interacts with factor B converting it into a clotting enzyme. 
Clotting enzyme cleaves coagulogen at two terminal of peptide C at the Arg–Lys and 
Arg–Gly forming insoluble coagulin gel. (c) The proteolytic activity feature of the 
activated clotting enzyme in horseshoe crab’s blood is used on synthetic chromogenic i.e. 
Gly–Arg–p-nitroaniline substrates instead of coagulogen to detect endotoxin as it 
separates p-Nitroaniline (p-NA). Upon addition of a chromogenic substrate, Ac-Ile-Glu-
Ala-Arg-pNA, the activated protease, clotting enzyme catalyzes the release of p-
nitroaniline (pNA), resulting in a yellow color that can be quantitated by measuring the 
absorbance at 405 nm (or absorbance at 340 nm) and extrapolating to a standard curve for 
correlating endotoxin concentrations (cont.). 
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1.2.3. Recombinant Factor C (rFC) Assay. rFC is an endotoxin sensitive 
synthetic protein that is cloned from factor C DNA to use as an alternative in vitro LAL 
test 47,73-77 . In the rFC test, the binding of endotoxin activates the synthetic rFC molecule, 
which then cleaves a fluorescein substrate (amino-methylcoumarin), resulting in the 
generation of a fluorogenic compound. The fluorescence is measured twice, first at time 
zero and then after the endotoxin has been introduced using excitation/emission of 
380/440 nm. The difference in fluorescence is proportional to endotoxin concentrations in 
the sample and is used to calculate a final endotoxin result. rFC is specific to endotoxin 
detection eliminating the dependence on nonspecific glycan binding like that in an LAL 
assay avoiding false positive results.78  The enzymatic sensitivity range to endotoxin is 
0.05-500 EU/ml.73 A comparison of rFC with various LAL assays is summarized in 
Table 1.1. Despite its lower limit of detection under laboratory conditions, the rFC assay 
is prone to contamination in field environments that severely compromise its analytical 
utility.79  
Table 1.1. A comparison chart eliciting three LAL test methods: the gel clot, 
turbidimetric and chromogenic method and rFC assay as available in commercial 
endotoxin detection kits. 
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1.2.4. Bovine Whole Blood Assay (bWBA). The test works by taking the whole 
blood from the animal and introducing it to a solution containing the pharmaceutical 
being tested 80.  In response to endotoxin, the white blood cells in the blood produce the 
cytokine Prostaglandin E2 (PGE2) in an inflammatory response, similar to that of humans 
81. The production of this cytokine is directly proportional to an increase in endotoxin 
concentration. According to several studies, the test is able to accurately detect 
endotoxins at concentrations of close to 0.25 EU/ml, whereas the concentration at which 
humans display symptoms of endotoxin exposure typically occurs around 0.30 EU/ml 81. 
This level of accuracy is very attractive for scientists looking to move away from LAL 
and RPT testing. The test also is easy to perform and takes few preparational steps 23.  
The storage of bovine whole blood seems to be a little less problematic than human 
whole blood after 24 h of storage time at 4 °C, when the PGE2 release is significant at 
>0.16 EU/mL 81,82. The test is not without its limitations. The whole blood needed for the 
tests can only be obtained from very young calves which makes it difficult to amass in 
vast quantities 83. Furthermore, due to cultural and religious practices, certain countries 
will not permit the collection or use of bovine blood. While its accuracy and ease of use 
is admirable, it still requires animal testing, and with the advancement of technology, this 
test may be replaced by other techniques. 
1.2.5. Monocyte Activation Test (MAT). The Monocyte Activation Test, or 
MAT, has been in development since 1995 84. The commercially available MAT kit 
involves using cryopreserved monocytes in human blood to test for a reaction to 
endotoxins. The response to endotoxins is determined by measurement of the induced 
pro-inflammatory cytokine Interleukin – 1β (IL-1β) using enzyme-linked immunosorbent 
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assay (ELISA) 85,86.  The ELISA is used by attaching a primary antibody to bind with the 
IL-1β released by monocytes in the presence of endotoxins, while a secondary antibody is 
linked with avidin-conjugated horseradish peroxidase (Avidin-HRP) enzyme that 
metabolizes tetramethylbenzidine (TMB) substrate and develops a blue-green to yellow 
color product 87. The absorbance of yellow color density is then measured at 450 nm by 
spectrometers, similar to a chromogenic LAL test 49. The test also has the added benefit 
of testing all pyrogens and inflammatory materials that would prove harmful to human 
patients 88,89. It avoids animal testing and has a detection of limit of as little as 10 EU/ml 
of endotoxin solution, and conveniently, this limit becomes even smaller, and the test 
becomes more accurate when using cryogenically-preserved human blood. This aids in 
storage and transportation of the human blood for testing if the blood can be cooled and 
preserved without sacrificing accuracy 85,90,91.  The monocytes can be prepared in a 
variety of ways. Some experiments have used whole human blood, while others use 
monocytes harvested from leukocyte filters at blood donation centers 90. This method 
displays high precision by being able to detect non-endotoxic pyrogens and their effect 
on possible patients of the tested material. However, as there is often a limited supply of 
human blood to be used for simply testing, inconsistencies can arise when using large 
quantities of blood are used 84,92. The most important limitation for the MAT is the short 
half-life (< 2 h) of viable monocytes in human blood in vitro. An alternative endotoxin 
ELISA kit such as the competitive ELISA (cELISA) is available that uses a microtiter 
well plate pre-coated with an anti-endotoxin primary antibody.93 Endotoxin containing 
sample or standards are added to the wells along with a fixed quantity of biotinylated 
detection antibody that competes for limited binding sites on the immobilized anti-
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endotoxin antibody. Avidin-HRP conjugate and TMB are used like that in ELISA to 
generate and measure color changes from blue to yellow. The absorbance reading of 
coloration at 450 nm is quantitated for endotoxin concentrations present in samples. 
1.3. BIOSENSOR TECHNIQUES 
In attempts to modernize endotoxin detection methods, scientists have begun to 
develop techniques designed around more synthetic approaches. They involve more 
technology as opposed to pre-existing natural pathways. These techniques represent the 
up and coming detection methods that scientists hope will eventually replace the gold 
standard of RPT and LAL tests. These techniques can be split into three categories, 
electrochemical, optical, and mass-based. 
1.3.1. Electrochemical. The majority of electrochemical biosensors are based on 
a principle called Electrochemical Impedance Spectroscopy, or EIS. Performing an EIS 
requires electrodes be placed within the solution desired to be tested and delivering a 
sinusoidal alternating current signal through the solution, usually ranging from 2-10 mV. 
By varying the frequency of these sinusoidal waves, an impedance spectrum can be 
created 94. The electrodes are coated in metal, to reduce electric resistance. Proteins that 
are highly selective to endotoxin components are then bound to these electrodes such that 
if the endotoxins come in contact with the electrode-protein complex, they bind to the 
proteins. These proteins are referred to as Endotoxin Neutralizing Proteins, or ENPs 95,96. 
When endotoxins bind to ENPs on the electrodes it increases the resistance of the 
electrode. This was the case in an experiment run by Yeo et al. 97 who constructed an 
electrode made of gold and a complex of human recombinant toll-like receptor 4 
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(rhTLR4) and myeloid differentiation-2 (MD-2) proteins (Figure 1.4). They exposed 
these electrodes to solutions of varying endotoxin concentrations and created impedance 
spectrums for each of these concentrations. The maximum current across all potential 
differences was lower at higher concentrations of endotoxin 86. The study also reports that 
this particular biosensor has high specificity towards endotoxins, in order to prevent false 
positive results. It then goes on to state that the sensor had a detection limit of 0.0002 
EU/ml. This is drastically lower than the standard LAL test limit of 0.03 EU/ml. A major 
limitation of this system is the single time use of electrodes once endotoxins are bound to 
TLR4-MD-2 complexes. Metal complexes immobilized upon a gold electrode have been 
used and were able to detect endotoxins at concentrations as low as 0.001 EU/ml  98. 
Porous silicon membranes (pSim) based electrochemical biosensors comprise of array of 
nano-channels which are modified using Polymyxin-B, with strong affinity to endotoxins. 
It shows the limit of detection of 18 EU/ml. These sensors showed ability to detect 
endotoxins from various bacterial strains like E. coli and S. typhimurium and all this is 
done in a label free manner 99. Studies have also reported highly sensitive peptide 
modified gold electrode based electrochemical biosensors which are used for endotoxin 
detection with very low limit of detection of 0.04 EU/ml 100.  These methods are faster, 
more accurate, and in most cases, more cost effective than biological based techniques 
101. Two other electrochemical techniques are amperometric and potentiometric methods. 
Amperometric transducers have been described as the most common of the 
electrochemical sensors used for endotoxin detection 102. They work on the relying on the 
same principle of EIS, wherein the concentration of the analyzed sample has a linear 
relationship with the current measured. This method is able to use premade, disposable 
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testing strips, for fast, cost-efficient testing 103. Potentiometric methods are worth noting 
because although their detection limits are relatively high, 1-5 EU/mL, they were the first 
biosensor to be able to detect endotoxins in real time 94,104. The methods in which the 
electrodes are created, as well as the ways in which they are measured and utilized, are 
more complicated and labor-intensive than the biological methods 105.  They require more 
sophisticated personnel and equipment to be run effectively than RPT or LAL tests106. 
 
Figure 1.4. A new electrochemical endotoxin sensor. (A) and (B) The design and 
fabrication of a new electrochemical endotoxin sensor based on a human recombinant 
toll-like receptor 4 (rhTLR4) and myeloid differentiation-2 (MD-2) complex. The 
rhTLR4/MD-2 complex, which specifically binds to endotoxin, was immobilized on gold 
electrodes through a self-assembled monolayer (SAM) technique involving the use of 
dithiobis (succinimidyl undecanoate) (DSU). (C) – (F) The electrochemical signals 
generated from interactions between the rhTLR4/MD-2 complex and the endotoxin were 
characterized by cyclic voltammetry (CV) and differential pulse voltammetry (DPV). (G) 
A linear relationship between the peak current and endotoxin concentration was obtained 
in the range of 0.0005 to 5 EU/mL with a correlation coefficient (R2) of 0.978. The 
estimated limit of detection (LOD) was fairly low, 0.0002 EU/ml. The rhTLR4/MD-2 
based sensors exhibited no current responses to dipalmitoylphosphatidylcholine (DPPC) 
bearing two lipid chains, which is structurally similar to endotoxin, indicating the high 
specificity of the sensors to endotoxin. Reproduced with permission from Ref. 78. 
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1.3.2. Optical Techniques. One such example is that of liquid crystal (LC) based 
optical sensor for highly sensitive endotoxin detection. LC based optical biosensors are 
developed using endotoxin specific single-stranded DNA aptamers which are the 
endotoxin selective probes of the biosensors. The LC based aptamer optical biosensors 
have linear endotoxin detection range from 0.05 to 1000 EU/ml and a detection limit of 
5.5 EU/ml. The biosensors have negligible cross-binding reactivity with the biomolecules 
thus maximizing their recovery 107. Broadly, these optical techniques can be divided into 
three distinct categories: luminescence, Surface Plasmon Resonance, and 
electrochemiluminescence that share the similar characteristic of relying on visual 
changes. 
1.3.3. Fluorescence and Luminescence Techniques. The bioluminescence 
method is based on the same principle of the LAL assay except the end point material 
(pNA) of LAL tests is used as the starting material for the mutant firefly luciferase 108,109. 
Luciferin-modified pNA has been designed as the substrate for a mutated version of the 
North American luciferase (Photinus pyralis) that can quickly and precisely identify 
solutions containing endotoxins by a bioluminescence reaction 109. The reaction generates 
high luminescence intensity and shows a luminescence 10 times as intense as the 
standard, wild-type luciferase 110. The lowest endotoxin concentration recorded was 
0.0001 EU/mL, while the researchers report a detection limit of this mutant-type 
luciferase bioluminescence technique was 0.0005 EU/ml 23. Another important factor to 
mention is that this detection limit was reported in 15 minutes. This required time is rapid 
in comparison to the LAL gel-clot techniques estimated required time of 138 minutes to 
nearly 1.5 hours 111.  Experiments have been performed using a peptide biosensor and 
  
17
attached fluorescent probes, fluorescein-maleimide (F5M), and tetramethylrhodamine-5-
malemide (TMR5M) 85. Recently, a fluorophore BODIPY ((4,4-Difluoro-1,3,5,7,8-
Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene) with excitation and emission wavelengths 
of 485/20 and 528/20 nm were used to quantify presence and removal of endotoxin from 
biological solutions (Figure 1.5) 112-115.  BODIPY dye which is a lipid biomarker, in 
presence of endotoxin quenches due to endotoxin binding to its surface signaling 
endotoxin contamination 112,113,116. The difference in the fluorescence of BODIPY which 
indicates the degree of quenching of the dye is plotted against the amount of 
corresponding endotoxin to generate standard curves. Endotoxin detection studies have 
been conducted using Alexa Fluor-labeled fluorescent endotoxin with excitation and 
emission wavelengths of 490 and 525 nm 117. In this study, C-18 acyl chain modified 
Fe3O4/Au/Fe3O4 nanoflowers were used for simultaneous capture and detection of 
endotoxins from water samples 117. The lowest endotoxin detection limit that was tested 
using this technique was 10 EU/ml 117.   
Figure 1.5. Fluorescent assay protocol for endotoxin detection. We have developed a 
fluorescence-based method that measures the changes in fluorescence intensity and the 
corresponding endotoxin concentration. The whole process is instantaneous and can 
detect endotoxin as low as 0.0001 ng/ml in solutions. 
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1.3.4. Surface Plasmon Resonance (SPR) and Mass-based Techniques. Zhang 
et al. have shown a smartphone biosensor platform using SPR. The disposable sensor 
chip utilizes the smartphone’s built in flash as a light source and a compact diffraction 
grating and spectra dispersive unit 118, but this technology is still in development. Recent 
publication regarding antibiotic mediated plasmonic biosensors for endotoxin detection 
have shown a low limit of detection of 40 EU/ml 119.  The plasmonic biosensor is based 
on a facile U-bent fiber optic probe (UFOP) technology that utilizes 
octadecyltrichlorosilanes (OTS) on the surface of optical fiber probes to hydrophobically 
entrap endotoxin from aqueous solutions. The binding of endotoxins has been monitored 
in real-time by measuring the change in refractive index (RI) in the evanescent layer 119. 
To add specificity and signal amplification, the bound endotoxins have been further 
tagged with antimicrobial polymyxin-B conjugated gold nanoparticles (PMB-AuNPs) in 
a sandwich format. The resulting evanescent wave absorbance-based fiber optic 
biosensor has excellent sensitivity with the total assay time of 1 h 119.  
 An example of mass-based techniques is electromagnetic piezoelectric acoustic 
sensors, or EMPAS that has been touted as being able to measure multiple types of 
pathogens, not exclusively endotoxins, as well as being able to detect endotoxins in real 
time within human blood plasma 120.  EMPAS uses ultra-high frequency acoustic wave 
sensing based on an ultrathin, oligoethylene glycol-based mixed surface platform coated 
on piezoelectric quartz discs. The glycol end on the surface of quartz has been 
functionalized with polymyxin B (PMB), a cyclic peptide antibiotic that shows high 
affinity for endotoxins and hence, has been used as the biosensor assay for endotoxin 
detection. Incubation of endotoxin-spiked whole blood with PMB-bead chemistry 
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resulted in the EMPAS resonant frequency shift (f) as a function of endotoxin 
concentration from 30-60 EU/ml 120.  Another mass-based method is magnetoelasticity 
that function by placing sensors directly on to dry testing surfaces, such as medical 
equipment or food. The sensor filaments, whose oscillation frequencies are monitored, 
fluctuate within a magnetic field. These sensors are coated in phages designed to bind 
with the target pathogen, like ENPs 121. When Salmonella typhimurium bind with the 
surface of sensors, the mass of sensor increases, resulting in a decrease in the sensor’s 
resonant frequency. The resonant frequency of the sensors has been measured wirelessly 
and compared with their initial resonant frequency. Control sensors without phage do not 
show any shifts in the resonance frequency and have been used to compensate for 
environmental effects and nonspecific binding 121. The resonant frequency change of 
sample measurement sensors has been reported to be statistically different from that of 
control sensors down to 5102 colony forming unit/ml, the detection limit for the work. 
The number of cells bound on the sensor surface have been imaged using scanning 
electron microscopy (SEM) that has been further verified the measured resonant 
frequency changes due to cell binding on the sensor surface. The total assay time of the 
presented methodology has been reported approximately 30 min. While the 
disadvantages of phage coated magnetoelastic sensor are non-regeneration of the surface, 
non-specificity and interferences from analytes, it may be advantageous as a disposable 
sensor due to low cost. 
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1.4. TECHNIQUES FOR DOWNSTREAM REMOVAL OF ENDOTOXINS 
Downstream process for pharmaceutical manufacturing comprises of three steps: 
(1) initial recovery by extraction or isolation, (2) purification and (3) polishing 1-3. 
Endotoxin removal presents a unique challenge, which form stable interactions with 
themselves and possibly with target therapeutics. 
1.4.1. Ultrafiltration. A single endotoxin molecule in its monomeric form has a 
molecular weight 10-30 kDa 22 depending on the core polysaccharides and 
oligosaccharide chain, but endotoxins have the ability to aggregate and form micelles and 
vesicles with molecular weights above 1000 kDa 29 and diameters up to 0.1 μm 20. The 
endotoxin micelles and vesicles can be separated from water, salts, and small target 
therapeutic molecules through size exclusion in ultrafiltration. Factors that affect the 
removal of endotoxins from aqueous solutions include the size distribution of the 
molecules in solution, the interactions between target molecules and endotoxin, 
therapeutic protein concentration and the presence of detergents.  The effect of protein 
concentration on the endotoxin removal efficiency using ultrafiltration membranes has 
been explored 22,122. Ultrafiltration membranes with 100 kDa molecular weight cut off 
(MWCO) has been used to filter endotoxin contaminated protein solutions with 
concentrations varying between 2-30 mg/ml. The % endotoxin removal in the filtration 
permeate through the membrane ranges from 28.9% to 99.8%, depending on the level of 
protein concentration and endotoxin dilution 22. The more dilute the protein samples are 
made, the higher is the rate of endotoxin removal due to the shift in equilibrium from 
endotoxin aggregates into monomers in dilute solutions and passing endotoxin monomers 
through the membrane.  
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Effects of detergent concentrations on the interactions between endotoxin 
molecules have been studied contributing towards efficient endotoxin removal. Multiple 
Tween 20 concentrations of 0.0%, 0.5%, 1.0%, and 2.0% have been added to the protein 
solutions to calculate the respective removal efficiency 22. An increase in the Tween 20 
concentration has led to an increase in the passage of endotoxin into the permeate and 
thus removing endotoxin from proteins 22. These results demonstrate that the presence of 
a detergents decreases the size distribution of endotoxin aggregates. As the detergent 
concentration has been increased, the equilibrium has shifted from micelles and vesicles 
to monomers 22,122. This method is undesirable for ultrafiltration where endotoxin 
monomers are to be trapped within the membrane and desired protein be allowed to pass 
as they are less likely to be stopped by the filtration membrane compared to endotoxin 
aggregates. 
Ultrafiltration has been used to separate endotoxin molecules from small target 
therapeutic drug molecules. For example, ultrafiltration has been utilized to separate 
endotoxin aggregates from BMS-753493, a small aqueous drug molecule with a 
molecular weight of 1.57 kDa 123. Two membrane sizes have been used to perform 
endotoxin decontamination of the drug molecules: 3 kDa and 10 kDa. The product 
permeates through the membrane while endotoxins are retained on the membrane. Both 
ultrafiltration membranes are effective in reducing the endotoxin concentration to below 
0.03 EU/mg but compared to the MWCO of 3 kDa, the 10 MWCO has higher drug yield 
of around 95% unlike the 3 kDa membrane which shows around 55% loss of the desired 
product  123 . Thus, ultrafiltration membranes are an  effective tool for removing 
endotoxins from aqueous drug molecules and other therapeutic products 123. 
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The main limitation associated with the ultrafiltration technique is that in most 
cases it can be used to remove endotoxins from molecules that are magnitudes smaller 
than endotoxin aggregates.  For this reason, this method is not applicable for most 
endotoxin separation scenarios. Ultrafiltration is best suited for removing endotoxin from 
water, salts, or small molecule therapeutics that do not have an affinity for endotoxin. 
1.4.2. Extraction. Solvent extraction is used to separate endotoxins from target 
therapeutics based on their relative solubilities in two immiscible liquids. Endotoxins 
form partition in the organic phase, while hydrophilic target molecules remain in the 
aqueous phase. Endotoxins have been effectively removed from the bacteriophages T4, 
HAP1, and F8 using 1-octanol with endotoxin removal efficiencies varying between 64 - 
99.9%. 36. Additional processing is required to remove any trace quantities of 1-octanol 
present in the aqueous phase as the presence of 1-octanol interferes with the LAL test for 
endotoxin detection 36. Even though solvent extraction technique gives high endotoxin 
removal from various therapeutics solutions, the product yield is significantly low and 
varies between 30-60% impacting the profits associated with the method where it may 
not be a practical choice for this application 36. 
Two-phase extraction using detergent Triton X-114, a non-ionic surfactant 124, has 
been explored to remove endotoxins from target therapeutics. Endotoxin was successfully 
removed from the green fluorescent protein using Triton X-114 and temperature 
transitions. Triton X-114 is miscible with water at a temperature of 0°C, but a phase 
separation occurs at temperatures above 23°C 125.  Endotoxins are partitioned in the 
detergent phase while the target therapeutics are partitioned in the aqueous phase.  
Endotoxin removal efficiencies using Triton X-114 ranged between 45-99% 125. In 
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addition to high endotoxin removal, Triton X-114 results in high product recovery of over 
80% 16.Triton X-114 isothermal extraction using sodium dodecyl sulfate (SDS) has also 
been very effective in removing endotoxins from pDNA with residual endotoxin 
concentration of around 16 EU/mg. Moreover, using this extraction technique, a pDNA 
recovery of over 80% was reported. While isothermal extraction was proven effective for 
plasmid-endotoxin removal, this method is not applicable for the removal of endotoxins 
from protein solutions because SDS completely denatures proteins causing significant 
changes to protein conformation 126. One major disadvantage of temperature transition 
extraction using Triton X-114 is that the repeated heating and cooling degrades 
therapeutic products 126. Extraction processes provide a rapid separation that is easily 
scalable and can achieve high removal efficiencies, especially with high initial 
concentrations 36,125,127. However, final endotoxin concentrations in the aqueous phase for 
both solvent extraction and Triton X-114 extraction remained above desired 
specifications, meaning additional processing is required.  
1.4.3. Ion Exchange Chromatography. Anion exchange chromatography can be 
used to separate negatively charged endotoxin molecules from positively charged 
molecules, such as basic proteins. Proteins exhibit different charges at different pHs. A 
protein exhibits a neutral charge if the pH is equal to its isoelectric point (pI), a negative 
charge if the pH is > its pI, and a positive charge if the pH is < its pI 128. The pI of an 
endotoxin molecule is ~2 16,20,129, meaning endotoxins are negatively charged under 
conditions typically encountered during chromatography. At pH < 2, the target protein 
exhibits a net positive charge and is repelled by a positive stationary phase while the 
negatively charged endotoxins interact with the stationary phase and leaves the column at 
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a lower velocity 130,131. Anion exchange chromatography is not ideal for removing 
endotoxins from negatively charged target molecules, such as pDNA or acidic proteins 
132,133. 
If significant ionic interactions are present between target proteins and endotoxins 
or between the protein and the resin, a decrease in protein yield or an insufficient 
separation may be observed. If the protein and the endotoxin have a strong interaction, 
endotoxins leave the column bound to the target protein. If there is a strong attractive 
interaction between the target protein and the resin, the protein yield is low 129. 
To lessen undesirable interactions, the pH of the protein solution is adjusted. The 
effects of resin volume and contact time in addition to pH and conductivity on the 
efficiencies of endotoxin removal have been explored for therapeutic products like, 
antigens NY-ESO-1, Melan-A, and SSX-2 129. The pIs of these antigens were 9.1, 8.7, 
and 6.2, respectively. NY-ESO-1 and Melan-A are both hydrophobic molecules while 
SSX-2 is hydrophilic 129. All tests were run using equilibrated Q XL resin. An increase in 
resin volume and endotoxin-resin contact time had a positive effect on endotoxin removal 
and the concentration of endotoxins in the permeate consistently decreased with increase 
in above variables. Low endotoxin concentration of ~ 0.4 EU/µg was obtained in the 
permeate and a protein recovery of > 80 % was obtained consistently at almost all resin 
volumes 129. While positively charged proteins are less likely to interact with the resin and 
remain in the column, they may also demonstrate an undesirable attraction to endotoxins. 
To minimize protein- endotoxin interactions, the pH chosen should be high enough to 
avoid giving the protein a strong positive charge. Effect of different pHs on the removal 
of endotoxin from protein Melan-A, a hydrophobic protein with a pI of 8.7 has been 
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studied. Melan-A exhibited a strong ionic interaction with endotoxins below its pI, 
causing endotoxins to leave the column with the target protein. To remedy this, the pH 
was increased to weaken such interactions 129. The pH tested were 7.9, 8.4, 8.9, and 9.2, 
which corresponded to endotoxin concentrations in the permeate of 1.4, 1.8, 0.6, and 0.5 
EU/µg 129. As the pH was increased above the protein's pI, the endotoxin concentration 
decreased dramatically and with no significant impact on the protein yield 129.  
The success of ion-exchange chromatography is highly dependent on the target 
molecule, but in general ion-exchange chromatography can achieve an endotoxin 
reduction of five orders of magnitude for concentrated solutions (>1,000 EU/ml) or three 
to four orders of magnitude from dilute endotoxin solutions (<100 EU/ml) 20. The resin 
involved with an ion exchanger can be regenerated by washing with detergents to 
separate endotoxins from the resin surface and additional washing steps 134. 
1.4.4. Affinity Chromatography. Affinity chromatography is used to separate 
endotoxins from target molecules using highly specific interactions between endotoxins 
and a ligand bound to a stationary phase 135. Because of the specificity of the ligand, there 
is little to no product loss during separation 35. The target therapeutic molecule will elute 
with a greater velocity than endotoxin molecules due to specificity. The ligand chosen 
should have a strong interaction with endotoxins and a weak interaction with the target 
therapeutic molecule at separation conditions. Affinity chromatography is applicable to a 
wide range of target molecules, including proteins and pDNA 136,137. 
It is important to note that the exact structure of endotoxins varies between 
bacteria strains based on the core polysaccharides and the long chain polysaccharide. For 
this reason, ligands are typically designed to interact 20 with the most conserved section 
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23,25,29,138 of the endotoxin molecule, Lipid A , through hydrophobic 129 and electrostatic 
interactions 20. Common ligands used in affinity chromatography include PMB, histidine, 
dimethylamine ligands, deoxycholic acid and polycationic ligands 17,139. Hydrophobic 
polymers in the form of nanoparticles have been explored for removing endotoxins from 
water and protein solutions.112,113 
One of the most commonly used ligands is PMB, a cyclic lipopeptide with a high 
affinity for endotoxin (Figure 1.6). As a ligand, PMB induces the dissociation of 
endotoxin aggregates 140 and binds to the Lipid A section of endotoxins 141 through 
hydrophobic interactions 142. PMB’s affinity to endotoxin can be attributed to the 
terminal amidine groups that are spaced such that interactions between amidine groups 
and the two phosphate groups on Lipid A can occur simultaneously 143. In addition to 
being used as a ligand, PMB is an antibiotic used to treat gram-negative bacterial 
infections. Despite PMB’s high affinity for endotoxin, columns utilizing PMB may 
experience a higher than average product loss 20. This is because there are positive 
charges on the amino acid groups on PMB that may attract negatively charged target 
molecules. Additionally, PMB is both neurotoxic and nephrotoxic, which may cause a 
problem if the ligand is released from the column 25. Work has been going on to develop 
peptides with similar compositions to PMB but with a decreased toxicity. These peptide 
analogs displayed a strong affinity to endotoxin as well as a decreased lethality when 
introduced intravenously into mice 144.  
The nitrogenous bases adenine, cytosine, histidine and histamine all display an 
affinity for endotoxin. Of these, histamine and histidine are equally as effective as  
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Figure 1.6. Chemical structures of various endotoxin binding ligands. Since endotoxins 
are negatively charged, anion exchange ligands are employed, e.g., diethylaminoethane 
(DEAE), polymyxin B, histamine, histadine, poly-l-lysine, polyethylimine (pEI) and 
chitosan. 
 polymyxin B and have been successful with separating endotoxin molecules from 
albumin, insulin, lysozyme, myoglobin, and others. Although histamine and histidine are 
considered equally effective, histamine is biologically active and may create 
immunogenic response in the body 20. On the other hand, histidine may work well for 
small sample volumes with a limited reduction of endotoxins, however, at the expense of 
large sample volumes, product losses cause low yield 20,138. Deoxycholic acid (DOC) is 
another ligand option that may offer a higher product recovery due to a low charge 
density that reduces ionic interactions with negatively charged proteins 20. While 
recombinant protein purification is primarily based on the use of tags, tag-free 
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alternatives have emerged as a convenient and popular approach because of less 
processing time.  Such an example is the purification of PspA4Pro protein with one step 
by washing contaminant proteins using a cationic detergent, cetyltrimethylammonium 
bromide (CTAB) and centrifugation to remove endotoxins in aggregates, or, cryo-
precipitation of contaminants in the precipitate and recovery of PspA4Pro protein in the 
supernatant 145.  Comparison of CTAB wash and cryo-precipitation with ion-exchange 
chromatography shows higher protein recovery (~92%) and intermediate recovery 
(47.8%) in CTAB and cryo-precipitation, respectively than 35-62% using 
chromatography 145. The % endotoxin removal were 96.5%, 99.9% and 99.5-99.9% for 
CTAB, cryo-precipitation and chromatography, respectively 145. This new strategy 
enables does not require the use of affinity tags, thus reducing the overall costs of protein 
purification. 
Cost effective ligand and its binding capacity are key factors for endotoxin 
removal in a purification process. Poly--lysine and polymyxin-B are two commonly 
used ligands in protein purification. Table 1.2 provides a reference list of these ligands 
with regards to endotoxin binding capacity, protein recovery, regenerability and cost that 
are commercially available for use in several different product names 112,113,115,146-151. 
Additionally, the contact time required between the solution and ligand will affect the 
cost. A process with a high contact time will required a larger column and therefore a 
greater initial investment. 
The pore size of the resin should also be considered. A small pore size will 
increase the retention of endotoxin in the column by size exclusion, while larger pore 
sizes will reduce the ionic interactions with anionic proteins 20. Studies have been 
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conducted to study the effect of pH and ionic strength solutions on endotoxin removal 
efficiencies from hemoglobin samples using an Acticlean Etox affinity column. 
Endotoxins have been reported to form stable complexes with hemoglobin, thus 
complicating separation 43,152.The effect of ionic strength on endotoxin removal 
efficiency and hemoglobin recovery have been studied using two different salt solutions 
(NaCl and CaCl2). The endotoxin removal efficiency displayed a decreasing trend as the 
ionic strength was increased. However, the endotoxin removal efficiency for CaCl2 
solutions displayed a more drastic initial decrease than that for NaCl solutions. These 
results indicate that not only do ionic interactions play a role in affinity chromatography, 
but the types of cations matter as well 43. 
Unlike the endotoxin removal efficiency, the ionic strength and cation type had a 
limited effect on the product recovery from hemoglobin-endotoxin solutions. For all 
endotoxin contaminated hemoglobin solutions tested, the recovery of hemoglobin showed 
an increasing trend as the ionic strength was increased. Beyond, the ionic strength of 0.10 
M, the hemoglobin recoveries remained relatively constant or displayed a gradual 
decrease with values over 95%. Though there existed interactions between endotoxins 
and hemoglobin that hindered separation but all the endotoxin contaminated hemoglobin 
solutions prepared with either NaCl or CaCl2 had hemoglobin recoveries above 99% for 
ionic strengths of 0.1 M, indicating that there is both an attraction between hemoglobin 
and the affinity resin and between hemoglobin and endotoxin which are weakened at an 
ionic strength of 0.1 M 43. 
The effect of pH on endotoxin removal efficiency and hemoglobin recovery was 
tested using different buffer solutions. The endotoxin removal efficiency of resins was 
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governed by the pI. There was a continuous and gradual decrease in endotoxin removal 
efficiency as the pH was increased from 4.5 to 8, and then the removal efficiency 
plummeted when the pH was increased from 8 to 9 because the pI of the affinity resin 
was 8. As the pH was increased from 4.5 to 8, the resin became less positively charged 
and was therefore less effective at attracting negatively charged endotoxins through 
electrostatic interactions but other affinity mechanisms were still present. As the pH was 
increased beyond 8, the resin moved from having a neutral charge to a negative charge 
that repelled endotoxins and overpowered some of the attractive affinity interactions. On 
the other hand, the pH or pI had a minimal effect on hemoglobin recovery; the recovery 
of hemoglobin from endotoxin solutions was above 97% for all pHs tested 43,143. 
Commercial resins employing hydrophobic and/or cationic ligands to remove 
endotoxin from proteins and biological solutions use porous nano and/or microparticles 
and have shown great promise in protein purification, but the type of ligand immobilized 
or incorporated within the matrix still governs its intravenous application. Many of these 
resins have shown reasonable endotoxin binding efficiency from therapeutic proteins and 
biological solutions but suffer from major shortcomings like low recombinant protein 
recovery and difficulty in intravenous application due to nephrotoxicity and neurotoxicity 
associated with the endotoxin binding ligands. Toxicity related shortcoming can surely be 
addressed by using biocompatible endotoxin selective polymers which are non-toxic. 
Another major concern associated with most of the porous resins used for endotoxin 
removal is that they come in packed bed form which suffer from major drawbacks like 
high pressure drop (due to combined effect of bed consolidation and column blinding) 
and poor mass transfer (as intraparticle diffusion is responsible for transport of solute to 
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the binding sites), thus making their application expensive and adding significant cost to 
downstream purification. 
The toxicity, pressure drop and mass transfer related shortcomings were 
addressed by using biocompatible, rigid and non-porous particles where adsorption takes 
place on the surface. One such study focused on using biocompatible and environment 
friendly polymer, poly--caprolactone (PCL) nanoparticles ~ 800 nm to remove 
endotoxins from water and protein solutions 112,113. The PCL nanoparticles (PolyBalls) 
were non-porous in nature and thus the endotoxin binding took place on the surface of the 
particles (Figure 1.7 (a)). PolyBalls showed high endotoxin removal efficiency of >99% 
from phosphate buffer saline (PBS) solution. These particles were also effective in 
removing endotoxin from protein solution prepared in water with more than 90% removal 
efficiency 112. The removal efficiency was >99% when protein solutions were prepared in 
phosphate buffer saline (PBS) 112. The research also reported high endotoxin binding 
capacity of ~ 1.5 × 10଺ endotoxin unit (EU) per mg of particles 112.  In addition to high 
endotoxin removal the particles offered high protein recovery in excess of 90% thus 
maximizing therapeutic product recovery. High endotoxin removal in presence of PBS 
was attributed to the creation of shielding effect in presence of lyotropic sodium chloride 
salt. Considering larger-scale industry applications, combinatorial techniques were 
applied to construct PolyBall containing flexible and multifunctional biofilters (Figures 
1.7 and 1.8). Contaminated samples were allowed to flow from one side of the filter to 
the other. The kinetics of endotoxin removal efficiency were determined as a function of 





Figure 1.7. PolyBall nanoparticles based effective endotoxin removal. (a) PolyBall 
nanoparticles are synthesized using the solvent diffusion method. (b) PolyBalls can be 
lyophilized in white powder form and stored at room temperature (~22 °C). (c) PolyBalls 
are effective in removing >99% endotoxins (> 2x106 EU/ml) from water (dotted line) and 
PBS (pH 7.4) (solid line). Change in LPS concentrations does not compromise PolyBall’s 
endotoxin removal efficiency. (d) PolyBalls efficiently remove endotoxins from a variety 
of protein solutions at different concentrations. (e) Removal of endotoxins does not affect 
protein recovery (>95% recovery) indicating minimal product loss and PolyBall’s 
specificity towards endotoxins even in endotoxin mixed protein solutions. (f) PolyBalls 
can be regenerated to remove endotoxins further. Figures reproduced with permission 
from Ref. 97 (Razdan et. al.). 
One major advantage of the biocompatible PolyBalls and multifunctional 
biofilters is that they can be reused for endotoxin binding quite effectively without a 
major loss in binding efficiency. PolyBalls can be regenerated by breaking endotoxin-
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Figure 1.8. PolyBall nanoparticles incorporated cellulose acetate (CA) membrane for 
effective endotoxin removal. (a) PolyBall nanoparticles are embedded in a cellulose 
acetate (CA) biofilter. (b) Cross-sectional view of a CA filter without any nanoparticles 
(negative control) using SEM. (c) SEM image of a biofilter with PCL nanoparticles 
impregnated in it. (d) Our biofilter removes >99% endotoxins (solid line) while filter 
without PCL nanoparticles (negative control) is not as effective as the biofilter in 
removing endotoxins indicating the role of PCL nanoparticles in binding and removing 
endotoxins from solutions. (e) Comparison of the endotoxin removal efficiency (solid 
line) and protein recovery (dotted line) between our filter and other commercial 
endotoxin removal filters. Our filter outperforms others while removing >99% 
endotoxins and maintaining >95% protein recovery. Figure reproduced with permission 
from Ref. 97 (Razdan et. al.). 
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Figure 1.8 (e) and Table 3 showcase a comparison of different endotoxin removal 
products in terms of binding capacity, protein recovery and cost. Although, non-porous 
particles solve the mass transfer related limitation but the problem of high pressure drop 
during purification operation still persists. Due to the specificity of the ligand, affinity 
interactions offer a low product loss with a wide range of applications. Both mixed-mode 
chromatography and membrane adsorption use similar mechanisms and experience 
benefits. 






1.4.5. Mixed-Mode Chromatography. Mixed-mode chromatography is a 
growing separation technique in the biopharmaceutical industry 45,153,154. While 
traditional chromatographic methods rely on a single dominant interaction between the 
ligand and the targeted molecule, mixed-mode chromatography (MMC) utilizes multiple 
interaction modes for an increased separation 45,154,155. When compared to traditional 
chromatographic methods, MMC offers an increased retention and selectivity of the 
targeted compound 156,157, especially for polar charged molecules 153,154. Many ligands 
used in affinity chromatography, such as histamine and histidine can be considered 
mixed-mode ligands due to their beneficial secondary interactions 133,157-159.  
1.4.6. Membrane Adsorption. Membrane adsorption exploits the same 
mechanisms used in affinity and ion-exchange chromatography, but offers a reduced 
processing time and initial investment. Similar to affinity chromatography, a product 
yield near 100% can be achieved 35,160. In membrane adsorption, the same ligands used in 
affinity chromatography or resins used in ion-exchange chromatography are bound to a 
support medium. The use of a membrane greatly improves flow rates and nearly 
eliminates diffusion limitations. Membranes can be made of nylon, PVA, PEVA, PVDF, 
cellulose acetate and cellulose 25,112,160. The membrane capsules are single-use, meaning 
there is no need for eluting, cleaning, or regenerating. Benefits of single-use membranes 
include a decreased chance of product contamination as well as a decreased process time 
and buffer volume due to the decrease in required cleaning steps 38. Membrane adsorption 
requires a low initial investment when compared to traditional chromatographic methods, 
but membranes must be continually purchased, which will affect manufacturing costs 38. 
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In the past, membrane adsorbers have not been widely adopted because it had a 
lower binding capacity than that of traditional chromatography methods. Endotoxin 
removal efficiencies of histidine immobilized on a nylon membrane for different 
endotoxin concentrations have been carried out. The ligand density for the membrane 
adsorbers studied was 7.38 mg/g. As the initial endotoxin concentration was increased, 
the removal efficiency was greatly decreased. This demonstrates the limited binding 
capacity using membrane adsorbers. Even at the lowest endotoxin concentration of 387 
EU/ml, the removal efficiency was only 65% 25. These results are consistent with those 
from previous studies that saw endotoxin removal efficiencies of approximately 70% 
with an initial endotoxin concentration of 6,000 EU/mL 161. Recently, membrane 
adsorbers with high efficiency endotoxin removal and binding have been synthesized. 
One such example of membrane adsorbers is that of amphiphilic carbonaceous particles 
(ACPs) incorporated in the polyvinylidene fluoride (PVDF) matrix. The absorbers have 
been successful at removing endotoxins from BSA protein solutions at >99.8% efficiency 
with >90 % protein recovery.160 Another study with PCL nanoparticle incorporated in the 
cellulose acetate membranes have been able to effectively remove endotoxins from water. 
The endotoxin binding capacity offered by the membrane adsorber was ~ 2.7 × 10଺  EU 
per mg particle compared to endotoxin binding capacity of ~ 1.4 × 10଺  EU per mg 
particle offered by PCL nanoparticles in suspension 112. 
1.5. DISCUSSION 
The biopharmaceuticals industry has experienced a rapid and consistent growth 
over the past few years 162-165. It is predicted that half of all drugs under development will 
  
38
be biopharmaceuticals within the next 5-10 years 3. Developing endotoxin removal 
methods that are both effective and cost efficient is an ongoing challenge 45 due to the 
high purity required and the potential interactions present between endotoxin and target 
molecules. Affinity and mixed-mode chromatography are the most promising methods 
for a widely applicable removal method due to the highly selective interactions between 
endotoxins and the chosen ligand. Additional research is still required to further develop 
additional methods for removal and ligands that demonstrate a high affinity to endotoxins 
with a low toxicity and cost. There is also ongoing research to develop endotoxin-free E. 
coli strains that would eliminate the need for endotoxin removal and decrease 
downstream processing costs 10,166,167. Another development is the use of alternative 
expression systems other than E. coli such as mammalian cell lines (e.g., Chinese hamster 
ovary and human embryonic kidney 293) or engineered yeasts 168. However, endotoxin 
contamination may originate from other sources such as additives, buffers, cell culture 
medium, reagents, serum, supplements and water 169. Therefore, biomanufacturing 
processes focus on developing innovative and effective technologies for in-line endotoxin 
detection sensors and removal of endotoxins and other contaminants from process 
solutions. 
Biological techniques led the way, starting with the RPT, a crude, yet effective 
method of testing medicines before injecting them into humans. This was a good start, 
but with a detection limit of 0.5 EU/ml, and taking over two hours to perform, as well as 
requiring live rabbits for test subjects, it was quickly outclassed by other methods. 
Following close behind RPT, was LAL assay testing. The LAL assay became the 
industry standard in medicine and equipment testing 170. A number of parental 
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pharmaceutical products such as Ampicillin, Cytarabine, Diclofenac, Dexamethasone, 
Heparin, Insulin, Gentamicin, Glucose, Saline solution, Vaccine, Vitamin, plasmid DNA, 
proteins etc. are routinely screened for endotoxin detection using LAL tests 171,172. It still 
falls short of being fast enough to keep up with the modern world of testing needs, not to 
mention the need to move away from using horseshoe crab blood in order to protect their 
dwindling population. bWBA and MAT are similar to LAL in that they fall short on 
keeping up with the needs of the modern world. While they present attractive qualities, 
MAT being able to use recycled monocytes from blood banks and bWBA requiring very 
little preparation, they still require collection and storage of blood from living beings. 
This would create difficulties in collecting proper amounts of blood stores to handle 
testing requirements. These traditional endotoxin detection assays also suffer from 
masking of endotoxins by the constituents present in drug formulations when spiked with 
endotoxins (LER phenomena) 62-64. This poses potential risks of underestimated 
endotoxin contamination in pharmaceutical products. Electrochemical techniques offer 
nearly endless combinations of sensor and protein-complexes, able to be designed 
specifically for a testing solution that could prove difficult for other tests. Optical 
detection methods offer incredibly high precision testing, with results ready in a matter of 
seconds, provided the equipment can be afforded and operated correctly. Finally, with the 
rise of mass-based resonance detection, the future of detection methods relies on more 
accurate, real-time detection, with increasingly cheap and easy to use. A reliable 
analytical method for endotoxin detection and analysis will also serve as a useful tool in 
the monitoring of drinking water purification processes and water reclamation plants. 
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There is no single purification method that fits all separation scenarios 173. The 
method chosen will depend greatly on the properties of the target molecule 139. 
Ultrafiltration is well suited for removing endotoxins from water, salts, or small molecule 
therapeutics, but it is not applicable to most separation scenarios. Extraction provides a 
high endotoxin removal efficiency for highly contaminated samples, but can possibly 
lead to an undesirable level of product loss. Ion Exchange chromatography provides 
adequate separation with acceptable product loss for molecules with a weak positive 
charge. Anion exchange chromatography is the most commonly used method for 
endotoxin removal. Endotoxin has been removed from plasmid DNA influenza vaccine 
solutions using ion-exchange chromatography with 97% purity and 47-88% yield 174,175.  
Due to the specificity of the ligands, affinity chromatography and mixed-mode 
chromatography offer an adequate separation with high product recovery for a wide range 
of therapeutic monoclonal antibodies. Membrane adsorption offers a reduced processing 
time and initial cost with a high product recovery, but has a low binding capacity that 
limits removal efficiencies. While there is no single method that is applicable to all 
scenarios, ion-exchange, affinity, and mixed-mode chromatography all offer consistently 
high removal efficiencies and product recoveries under appropriate operating conditions. 
Even so, additional research is needed to develop more widely applicable and cost-
effective methods that reduce product loss while meeting all governing regulations for 




There is an increased demand for techniques capable of producing quality 
products at a decreased cost. This is especially true for biopharmaceuticals produced 
using gram-negative bacteria, where endotoxin contamination is a concern. Animal-based 
endotoxin detection techniques will become obsolete in favor of electronic biosensors or 
fluorescence-based techniques. Developing endotoxin removal methods that are both 
effective and cost efficient is an ongoing challenge due to the high purity required and the 
potential interactions present between endotoxins and target molecules. Affinity and 
mixed-mode chromatography are the most promising methods for a widely applicable 
removal methods due to the highly selective interactions between endotoxins and the 
chosen ligand. Additional research is still required to further develop additional methods 
for removal and ligands that demonstrate a high affinity to endotoxins with a low toxicity 
and cost. These innovations will allow for an increase in product quality and yield with a 
decrease in manufacturing cost. 
1.7. DISSERTATION OVERVIEW 
In paper-1, biocompatible and recyclable polymeric polycaprolactone (PCL) 
nanoparticles (NPs) (𝑑௉ = 780 ± 285 𝑛𝑚) were synthesized at a relatively low cost and 
demonstrated to possess sufficient binding sites for endotoxin adsorption and removal 
The PCL NPs removed ~82% and ~90% endotoxins from water and protein solution 
using only one milligram (mg) of NPs, which was equivalent to ~1.23 × 10଺ and 
~1.45 × 10଺ endotoxin units (EU) per mg of particle. The endotoxin removal efficacy 
increased to a higher level (~98% and ~99%) when phosphate buffered saline (PBS; 150 
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mM NaCl) was used in place of water and in proteins. In addition to high endotoxin 
removal efficiency the protein recovery values were > 95 % for a wide concentration 
range of protein solutions (20 – 1000 g/ml). The PCL NPs were also highly effective in 
different buffers and pHs. To scale up the process even further and increase the 
throughput, PCL NPs were incorporated into a matrix of cellulose acetate membrane 
which enhanced the endotoxin adsorption further up to ~100% just by running the 
endotoxin-containing water through the membrane under gravity. 
In paper-2, The goal was to test the validity of the hypothesis that synergistic 
combination of van der Waals and hydrophobic interactions were responsible for 
endotoxin binding on polycaprolactone (PCL) nanoparticle’s (NPs) surface.  This 
hypothesis was tested by evaluating endotoxin removal efficiency of a material which 
shows surface hydrophobicity similar to that of PCL NPs. Polystyrene (PS) 
nanoparticles,~ 800 𝑛𝑚, with surface properties similar to PCL NPs were used as a 
control to test the hypothesis.  Additionally, this work demonstrated that acidic (pH 2.8) 
and basic (pH 11.5) conditions do not have a major impact on protein recovery using 
PCL NPs. Six different types of proteins with molecular weights varying from 14 kDa 
- 341 kDa and isoelectric points (pI) from 4.5-10.7 showed protein recovery > 92 % 
under extreme operating pH. Finally, in order to increase the throughput and address the 
mass transfer limitations, the PCL NPs incorporated cellulose acetate (CA) biofilter were 
synthesized and applied to different protein solutions with a maximum endotoxin 
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ABSTRACT 
The presence of endotoxin, also known as lipopolysaccharides (LPS), as a side 
product appears to be a major drawback for the production of certain biomolecules that 
are essential for research, pharmaceutical, and industrial applications. In the 
biotechnology industry, gram-negative bacteria (e.g., Escherichia coli) are widely used to 
produce recombinant products such as proteins, plasmid DNAs and vaccines. These 
products are contaminated with LPS, which may cause side effects when administered to 
animals or humans. Purification of LPS often suffers from product loss. For this reason, 
special attention must be paid when purifying proteins aiming a product as free as 
possible of LPS with high product recovery. Although there are a number of methods for 
removing LPS, the question about how LPS removal can be carried out in an efficient and 
economical way is still one of the most intriguing issues and has no satisfactory solution 
yet. In this work, polymeric poly-ε-caprolactone (PCL) nanoparticles (NPs) (𝑑௉ = 780 ±
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285 𝑛𝑚)  were synthesized at a relatively low cost and demonstrated to possess sufficient 
binding sites for LPS adsorption and removal with ~100% protein recovery. The PCL 
NPs removed greater than 90% LPS from protein solutions suspended in water using only 
one milligram (mg) of NPs, which was equivalent to ~1.5 × 10଺ endotoxin units (EU) 
per mg of particle. The LPS removal efficacy increased to a higher level (~100%) when 
phosphate buffered saline (PBS containing 137 mM NaCl) was used as a protein 
suspending medium in place of water, reflecting positive effects of increasing ionic 
strength on LPS binding interactions and adsorption. The results further showed that the 
PCL NPs not only achieved 100% LPS removal but also ~100% protein recovery for a 
wide concentration range from 20 – 1000 μg/ml of protein solutions. The NPs were 
highly effective in different buffers and pHs. To scale up the process further, PCL NPs 
were incorporated into a supporting cellulose membrane which promoted LPS adsorption 
further up to ~100% just by running the LPS-containing water through the membrane 
under gravity. Its adsorption capacity was ~2.8 × 10଺ EU/mg of PCL NPs, 
approximately 2 -fold higher than that of NPs alone. This is the first demonstration of 
endotoxin separation with high protein recovery using polymer NPs and the NP-based 
portable filters, which provide strong adsorptive interactions for LPS removal from 
protein solutions. Additional features of these NPs and membranes are biocompatible 
(environment friendly) recyclable after repeated elution and adsorption with no 
significant changes in LPS removal efficiencies. The results indicate that PCL NPs are an 
effective LPS adsorbent in powder and membrane forms, which have great potential to be 





In biotechnology industries, gram-negative bacteria are widely used for the 
production of therapeutic biomolecules including proteins, peptides, and nucleic acids1–6 . 
These biomolecules are recovered by cellular rupturing that leads to the release of a large 
number of bacterial cell-wall components containing endotoxins, also known as 
lipopolysaccharides (LPS)7–9 . When the LPS contaminated products are administered to 
animals or humans even in small quantities (0.05–0.1ng/ml), a systemic inflammatory 
reaction can occur, leading to multiple pathophysiological effects, such as septic shock, 
tissue injury, and lethality10,11. Removing undesirable LPS from solutions is thus an 
important aim in the pharmaceutical industry and in clinical practice. Conventional 
treatments such as coagulation and membrane filtration are adequate for removing 
bacteria cells and debris but not effective for removing dissolved endotoxins to a 
significant extent. Therefore, it is highly desirable and also the focus of this project to 
develop a biodegradable and inexpensive means that can tackle both aspects of LPS 
removal. 
A number of approaches have been developed and typically utilized to reduce 
LPS concentration in pharmaceutical solutions and therapeutic products or in purified 
water8,12–33. These approaches employ activated carbon34,35, gel filtration 
chromatography12–15, ion exchange or size exclusion chromatography16–20, sucrose 
gradient centrifugation36–38, Triton X-114 phase separation39–41, ultrafltration21,22, 
microfltration21,22 and affinity adsorbents23–28, functionalized with L-histidine42, 
poly(ethylene imine) (pEI)23, poly-ε-lysine, poly(γ-methyl L-glutamate), or polymyxin 
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B8,29–33 and chemical means such as ozonation and chlorination35,43. More recently, 
nanoparticle (NP)-based methods have also been attempted and shown great promise44–46. 
Polymyxin B capped silver (Ag) NPs have been used to remove LPS from aqueous 
solutions, up to 97% efficiency, based on the ionic interaction between the cationic 
peptide on Polymyxin B and the anionic phosphate on Lipid A of LPS44. Surface 
modified iron oxide (Fe3O4) gold (Au) core-shell nanoflowers (NFs) have been explored 
for simultaneous reduction and detection of LPS as alternatives to classical methods of 
endotoxin sensing47. Also, NPs with a polystyrene core and a polyglycidyl methacrylate 
shell have been synthesized and further modified with amine-based, amino acid based, 
PEI, tetracaine, or Polymyxin B ligands for LPS removal from water and salt solution46. 
The parent particles modified with amine-based (ethylene diamine, hexamethylene 
amine, and dodecyl diamine) and PEI ligands showed significant LPS removal efficiency 
around 90% from both water and salt solution, whereas those modified with tetracaine, 
amino acid lysine, and amines (histamine and tryptamine) showed a higher LPS removal 
efficiency from water, also around 90%, than from salt solution46. While showing great 
promise, these approaches at present still have their shares of limitations and 
disadvantages in terms of cost, efficiency, degradability, side effects, and/or 
accompanying toxicity brought by the reagents. For examples, the methods utilizing 
porous functionalized NPs are reasonably effective in reducing the LPS concentration; 
however, their operations are relatively expensive due to the use of high-pressure 
equipment that adds significant cost to downstream purification and are contingent on the 
slow processes of intraparticle diffusion and solute retention on the binding sites48–50. 
Polymyxin B, a polypeptide antibiotic, can also cause neurotoxicity and nephrotoxicity. 
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A key step forward with the NP-based approach is to establish a high throughput, low-
cost method that is not subject to high pressure-drop limitation, slow solute transport, or 
accompanying toxicity. To this end, poly-ε-caprolactone (PCL) NPs without any 
modification have been manufactured in the PI’s laboratory, which are non-porous solid 
adsorbent nanoparticles with solute binding sites situated on the particle surface. The NPs 
were found to be capable of adsorbing and removing LPS from protein solutions at 
efficiency up to 100%. Their prospects for technological application were further 
substantiated by the processing feasibility of incorporating PCL NPs into membrane 
filters and high LPS reduction and removal from biological solutions using cellulose 
membranes embedded with PCL NPs. In either powder form or in a spread bed of a fat 
sheet membrane, PCL NPs offer high adsorption capacity per unit mass of the adsorbents. 
Since PCL and cellulose are both low-cost biocompatible polymers51–53, the use of such 
PCL NP-embedded membranes represents a novel LPS separation system that requires 
low capital costs but provides desirable ease of manufacturing, excellent performance, 
disposability, and biodegradability. 
 
2. MATERIALS AND METHODS 
2.1. SYNTHESIS OF PCL NANOPARTICLES 
PCL NPs were synthesized by the solvent evaporation method which utilized 
high–speed homogenization and sonication, followed by solvent evaporation, 
centrifugation to remove surfactants, and then lyophilization.54-58 A PCL solution at a 
concentration of 10 mg/ml in ethyl acetate was injected using a syringe pump to a 1% 
  
48
w/v polyvinyl alcohol (PVA) solution prepared with reverse osmosis (RO) water. The 
mixture was homogenized by using a homogenizer rotating at 3000 rpm while being 
placed in a sonication bath. Ethyl acetate was removed by stirring the mixture at 300 rpm 
for two days. The obtained particles were washed five times using RO water and 
centrifuged for 30 minutes at 10,000 rcf. The resulting products were freeze-dried, 
weighed, and stored at 4ºC until further use. To test the effects of cationic charges on 
bare PCL NP, 10 mg of freeze-dried PCL NPs were coated with cationic PLL solution by 
incubating with 1 ml of 0.1 % (w/v) PLL (Sigma) for 1 h. Post incubation the particle 
suspension was centrifuged for 30 min at 16,000 rcf and the supernatant was separated to 
obtain positively charged PLL coated PCL NPs. 
2.2. CHARACTERIZATION OF PCL NANOPARTICLES 
The morphology of PCL NPs was observed using Hitachi S-4700 scanning 
electron microscope (SEM) at an accelerating voltage of 15 kV. Samples were sputter 
coated with Denton Au/Pd coater before inserting it into the microscope. The average 
PCL particle size was measured by analyzing the SEM images using the ImageJ software 
(version 1.51w). The average particle size was reported as mean ± standard deviation 
(SD) based on the diameters of 200 randomly selected particles. The hydrodynamic size 
and surface charge of NPs were characterized by dynamic light scattering (DLS) and zeta 
(𝜁) potential measurements, respectively using Malvern NanoZS90 Zetasizer. The 
hydrodynamic diameter of PCL NPs was measured at 25ºC using He-Ne Lasers at 90º 
scattering angle. The size distribution was obtained based on three independent 
experiments utilizing 100 successive runs. Zeta potential values were reported based on 
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three independent experiments with each experiment utilizing 15 successive runs and the 
results were reported as millivolts (mV) ± SD. 
2.3. ADSORPTION STUDIES 
Escherichia coli O111 : B4 LPS (Sigma Aldrich) was used to study the adsorption 
capacities of PCL NPs in aqueous solutions in batch experiments. Initial experiments 
were carried out using a constant LPS concentration (150 µg/ml) treated with different 
PCL concentrations (0.1, 25, 50, 100, 200, 300, 400, 500, 750 and 1000 μg/ml) in: (i) RO 
water (pH ~6); (ii) phosphate buffered saline (PBS; 150 mM, pH ~7.4); (iii) bovine 
serum albumin (BSA) solutions in water and PBS; (iv) Trastuzumab (TTZ; Genentech) 
solutions in water and PBS; (v) Fibrinogen (Alfa Aesar) in PBS and (vi) Human 
Hemoglobin (MP Biomedicals) in PBS. The composition of PBS is as follows: 137 mM 
NaCl, 10 mM phosphate, and 2.7 mM KCl at 25°C. The LPS binding capacity to PCL 
NPs was analyzed using Bodipy (BOD) fluorescence displacement assay technique.58,59 
BOD is a fluorescent molecule that quenches its fluorescence intensity (F.I.) when it 
binds to LPS. The F.I. of BOD was used to determine the LPS concentration in solution 
using a known standard calibration curve (Figure. S1 and Figure. S2). The F.I. 
measurements were carried out using a microplate reader (BioTek). Excitation and 
emission wavelengths for BOD were 485/20 and 528/20 nm, respectively. RO water was 
used as a negative control. The background fluorescence intensities were subtracted to 
avoid any interferences. The percentage (%) LPS removal by PCL NPs from water and 
PBS was calculated using equation (1): 
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The % LPS removal by PCL NPs from protein solutions was calculated using 
equation (2): 
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where 𝐹𝐼஻ை஽ , 𝐹𝐼஻ை஽,௉௥௢௧௘௜௡,௅௉ௌ, and 𝐹𝐼஻ை஽,௉௥௢௧௘௜௡,௅௉ௌ.௉஼௅ represent the F.I. of BOD 
alone, LPS mixed with BOD and protein, and LPS mixed with BOD, protein and PCL 
NPs, respectively. 
The adsorption capacity at equilibrium (𝑞௘) was evaluated using the following 
equation: 
 




    3  
 
where 𝐶଴, 𝐶௘ , 𝑊, and 𝑉 represent the initial LPS concentration (g/ml), the 
corresponding LPS concentration at equilibrium (g/ml), the PCL NP’s mass amount 
(mg), and the solution volume (ml), respectively.  The isotherm data were fitted into 
the linear Freundlich model equation (4) to describe the adsorption equilibria:                                                                           
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where, 𝑞௘, 𝐾, 𝑛 and 𝐶௘ represent the adsorption based binding capacity (g LPS per 
mg PCL NPs), Freundlich (binding affinity) constant (μg LPS per mg PCL NPs), 
Freundlich exponent and equilibrium LPS concentration (μg LPS/ml solution), 
respectively. 
2.4. PROTEIN RECOVERY 
Protein recovery in LPS spiked sample solutions was quantified using BCA assay 
kit (Pierce). The absorbance at 562 nm was measured in a microplate reader (BioTek). 
Different concentration of BSA, TTZ, fibrinogen and human hemoglobin were used for 
plotting the individual protein’s standard curves (Figure. S3). All assays were performed 
by the manufacturer’s instructions. 
2.5. EFFECTS OF BUFFER AND pH ON LPS REMOVAL 
The effect of different buffers on LPS binding efficiency was analyzed by 
interacting a fixed PCL NP concentration (1000 µg/ml) with a constant LPS 
concentration (150 µg/ml) prepared using different buffer solutions recipes (Table S1) 
each having fixed ionic strength of 100 mM (0.1 M). Six different buffer pH values from 
2.8-9.6 were tested. Glacial acetic acid was used to obtain a pH value of 2.8. Phosphate 
buffers were prepared from monobasic and dibasic salts of 0.2 M sodium phosphate to 
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obtain pH values of 5.8, 6.8 and 8.60-62 PBS of sodium bicarbonate were used to prepare 
pH 7.4 and 9.6 buffers, respectively.60-62 
2.6. EFFECT OF SALT CONCENTRATION ON PROTEIN RECOVERY 
To investigate the effect of salt concentration on % protein recovery, 1000 μg/ml 
of each BSA and TTZ were spiked with 150 μg/ml of LPS in the different range of PBS 
concentrations: 0, 0.1, 1, 10, 100 and 150 mM. Protein concentrations were measured 
before and after LPS spiking and used to further calculate the % protein recovery. 
2.7. PCL NP REGENERATION STUDIES 
PCL NP suspension was interacted with fixed LPS concentration (270 µg/ml) in 
RO water and then centrifuged to obtain the supernatant which was reacted with BOD to 
calculate the percent LPS removal efficiency using equation (1). The PCL NP pellet was 
resuspended in 0.2 N sodium hydroxide (NaOH) solution for 2 h and then centrifuged to 
remove the NaOH supernatant. The PCL NP pellet was washed five times using RO 
water before reusing it again for LPS binding. This regeneration cycle was repeated three 
times to measure any loss in LPS binding efficiency for PCL. The LPS removal 
efficiency of PCL NPs after each washing cycle was measured using the BOD 
fluorescence assay. 
2.8. SYNTHESIS OF CELLULOSE ACETATE (CA) MEMBRANE 
The CA membranes with or without PCL NPs were prepared by a non-solvent 
induced phase separation process.63 A casting solution was prepared by dissolving 10 
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wt.% each of CA and 5 wt.% Pluronic F127 in dimethyl sulfoxide (DMSO) (control). For 
membranes with NPs, 1 wt.% of PCL NPs was dispersed in the casting solution under 
vigorous stirring (1100 rpm) at 50ºC for 1 h to allow homogenous mixing and the 
solution was then left for 2 h to allow the complete release of bubbles. The final solution 
was cast on a casting plate and then immersed in RO water coagulation bath for 30 min. 
Finally, the water wet membrane was immersed in 30% glycerol (plasticizer) for 15 min, 
which in addition to improving the mechanical properties also help in dry storage of the 
membrane for at least 300 days with no major loss in membrane flux and removal 
properties.64 The mass loading of PCL NPs in CA membranes was quantified by 
comparing the weights of 10 randomly freeze-dried membrane pieces of the same area 
(1.8 cm2) before and after adding the NPs. The measured weight difference of the 
membranes with and without NPs is the mass of PCL NPs added to the membrane and 
was used to calculate LPS removal per unit mass of PCL NPs. 
2.9. MICROSCOPY AND MICROANALYSIS 
The CA membranes with or without PCL particles were dried using the freeze-
fracture method.65 Samples were attached to an SEM stub and sputter coated with Denton 
Au/Pd coater. The membrane surface and cross sections were imaged using the Hitachi S-
4700 SEM operated at 3 kV. The membrane surface and cross-sectional morphology, 
pore size, and thickness were analyzed using ImageJ software (version 1.51w). The 
average membrane pore size and thickness were based on 100 randomly selected pores 
and points from different images. The results were reported as average ± standard 
deviation (SD). The presence of PCL NPs in the membrane was further verified using 
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fluorescein isothiocyanate (FITC; 1wt%) incorporated PCL NPs and fluorescence 
microscopy (Zeiss) equipped with 470 ± 40/525 ± 50 nm excitation/emission filters. 
2.10. PERMEATION STUDIES 
The measurement of permeation flux was conducted using a custom-made 
membrane test apparatus (Figure. S4). The apparatus was made of two polyvinyl chloride 
flow pipes that hold the membrane in between like a sandwich. Each flow pipe is 1.5 cm 
wide. The top and bottom pipes are 20 cm and 10 cm long, respectively. The membrane 
area was 1.8 cm2. In each experiment, a volume of 20 ml water or solution was fed to the 
top pipe in a batch setup and flowed through the membrane by gravity. For LPS mixed 
water, a concentration of 270 μg/ml LPS in 20 ml water was used. Water was collected 
from the end of the bottom pipe. The water volume was measured at 1 h interval for 8 h 
to calculate the change in water flux. 
2.11. QUANTIFICATION OF LPS REMOVAL USING PCL NPs IN CA 
MEMBRANES 
The determination of LPS removal by CA membranes with or without PCL 
particles was also carried out by BOD fluorescence displacement assay technique58,59 and 
the apparatus introduced above. A volume of 20 ml RO water containing 270 μg/ml of 
LPS was fed to the top flow pipe to flow through a sandwiched membrane by gravity. A 
fixed volume (277 µL) of the LPS feed and the permeate was collected every hour until 8 
h. The samples were mixed with BOD (262.11 µg/ml) and the F.I. of BOD was measured 
using a plate reader (BioTek). The percent (%) LPS removal was calculated using 
equation (5),                           
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where 𝐹𝐼஻ை஽,  𝐹𝐼஻ை஽.௅௉ௌ ௜௡ ௣௘௥௠௘௔௧௘, and 𝐹𝐼஻ை஽.௅௉ௌ ௜௡ ௙௘௘ௗ are the F.I.s of BOD alone, 
BOD mixed with LPS in permeate, and BOD mixed with LPS in the feed solution, 
respectively.  Each value used here was based on triplicate measurements from three 
independent experiments. The mean differences and standard deviations were also 
evaluated. 
2.12. CALCULATION OF LPS REMOVAL EFFICIENCY PER UNIT MASS AND 
SURFACE AREA OF PCL NPs 
The LPS removal efficiency per unit mass and surface area were calculated for 
PCL NPs used in powder form or in the CA membrane. This required the calculation of 
the number of PCL NPs per unit solution volume using equation (6). 
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where 𝑐 is the concentration of particles in solution in g/ml, 𝜌 is the density of PCL NPs 
in g/ml, and 𝑑௣ is the particle diameter in µm. The mass loading of PCL NPs entrapped 
in a CA membrane was measured from the mass difference of the freeze-dried CA 
membranes with and without NPs. The LPS removal efficiency per unit cm2 and per unit 
milligram of NPs was calculated based on the mass of LPS in the feed solution and the 




3.1. REMOVAL OF LPS FROM WATER AND PBS USING PCL NPs IN 
POWDER FORM 
The size of PCL NPs was observed to be 780 ± 285 nm in diameter by analyzing 
SEM images (Figure. 1a) and DLS technique (Figure. 1b), which, relatively speaking, is 
fairly uniform with a low level of dispersity in size. The surface morphology shows that 
the NPs were of highly spherical shape and their surfaces appeared to be closely packed 
without apparent pores leading into the interior of the particles. The 𝜁 potential of PCL 
NPs was found to be −20 ± 5 mV in water (Figure. 1c) indicating a stable dispersion that 
resists aggregation. LPS adsorption tests were carried out with PCL NPs in both water 
(open circles; dotted line; Figure. 2a) and PBS (filled, solid 265 circles; solid line; Figure. 
2a) where initially the concentration of PCL NPs was systematically varied from 0 to 
1000 μg/ml in both cases at a fixed LPS spiked concentration of 150 μg/ml and then the 
concentration of PCL NPs was fixed and the concentration of LPS was varied from 0.1 to 
150 μg/ml in RO water. It was clear and important to note first that PCL NPs were 
effective in adsorbing and removing LPS from solutions regardless of the presence or 
absence of salts (PBS). In general, the removal efficiency of LPS by PCL NPs increased 
with increasing PCL NP concentration, which was to be expected due to increasing 
numbers of active sites available in the system for binding to LPS. The maximum level of 
LPS removal achieved was 98% when the PCL NP concentration of 𝑐=1000 μg/ml was 
used under the positive influence of salts. Without salts, the LPS sequestration from 
water was only ~1.8% at a low NP concentration of 0.1 μg/ml and increased to 9% and 
82% when the NP concentration became 100 and 1000 μg/ml, respectively. The result 
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at 𝑐 =1000 μg/ml was used to evaluate the LPS removal efficiency with varying LPS 
concentrations of 0–150 μg/ml in water (Figure. 2b). The maximum LPS removal 
efficiency was ~95%, which was approximately ~ 2040 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑢𝑛𝑖𝑡𝑠 (𝐸𝑈)/𝑐𝑚ଶ or 
~1.3 × 10଺ 𝐸𝑈/𝑚𝑔 of PCL NPs (Table S2).Across the whole concentration range, the 
LPS adsorption increased with the addition of salt (PBS; pH 7.4) to water (solid circles; 
Figure. 2a). This positive effect was clearly exhibited by the data beyond any uncertainty 
of measurement and indicated that increased ionic strength by the addition of salts 
resulted in higher LPS adsorption on the PCL NP surface. It is possible that at this high 
salt concentration (150 mM PBS) a strong interaction between water molecules and salts 
creates a shielding off effect leaving less water available for the induction of interactions 
between LPS and PCL. This behavior is consistent with the previously published 
literature.66-71 Another possible explanation could be an electrostatic screening effect that 
reduces the repulsive interaction between two moieties carrying the same type of charges. 
Although both LPS and PCL can generally be considered hydrophobic molecules, the 
former exhibits a net negative charge due to its phosphate groups 33 and the latter also 
possesses partial negative charges in its carbonyl oxygen atoms. The repulsion between 
these negative charges can be understood to be weak relative to the van der Waals and 
hydrophobic binding46 between the two massive molecules and hence unable to impede 
the overall binding interaction and adsorption between LPS and PCL. However, this 
repulsion can be further weakened, thereby giving rise to stronger binding interaction and 
heightened adsorption, by the presence of salt ions in proximity to the negative charges 
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Figure 1. Characterization of PCL NPs. (a) An SEM image of PCL NPs at 50,000 X 
magnification. (b) Plot showing size distribution of PCL NPs. (c) Zeta potential of PCL 





Figure 1. Characterization of PCL NPs. (a) An SEM image of PCL NPs at 50,000 X 
magnification. (b) Plot showing size distribution of PCL NPs. (c) Zeta potential of PCL 
NPs in water. Three colors indicate three independent runs (cont.).  
(a) 
 
Figure 2. The LPS removal efficiency of PCL NPs from water and PBS. (a) The percent 
(%) LPS removal from water (open circles, ○; dotted line) and PBS (filled, solid circles, 
● ; solid line) following adsorption on PCL NPs. *** indicates the p-value < 0.005 
showing a statistically significant difference between % LPS removal in water and PBS. 
A fixed LPS concentration of 150 μg/ml was used in this study. (b) Water containing low 
(0.1 μg/ml) to high (150 μg/ml) LPS concentrations were treated with 1000 μg/ml of PCL 





Figure 2. The LPS removal efficiency of PCL NPs from water and PBS. (a) The percent 
(%) LPS removal from water (open circles, ○; dotted line) and PBS (filled, solid circles, 
● ; solid line) following adsorption on PCL NPs. *** indicates the p-value < 0.005 
showing a statistically significant difference between % LPS removal in water and PBS. 
A fixed LPS concentration of 150 μg/ml was used in this study. (b) Water containing low 
(0.1 μg/ml) to high (150 μg/ml) LPS concentrations were treated with 1000 μg/ml of PCL 
NPs that gives ~95% LPS removal (cont.). 
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3.2. REMOVAL OF LPS FROM PROTEIN SOLUTIONS USING PCL NPs 
To study the effectiveness of PCL NPs on removing LPS at the common 
contamination level from 0–150 μg/ml in biopharmaceutical solutions, two protein 
solutions were investigated. For this purpose, BSA and TTZ protein solutions (~1 mg/ml) 
in PBS of pH 7.4 and RO water containing either low or high levels of LPS were exposed 
to 1000 μg/ml PCL NPs (Figure. 3a). It is worth noting that the % LPS removal was 
higher (90–100%) in PBS (solid lines, Figure. 3a) than in water (dotted lines, Figure. 3a) 
indicating that PCL NPs were effective in removing LPS from pharmaceutical protein 
formulations.72 We further tested the effects of protein concentration on LPS removal by 
analyzing four different protein solutions spiked with a fixed concentration (150 μg/ml) 
of LPS (Figure. 3b). Increasing protein concentrations from 250 to 1000 μg/ml did not 
alter the ~90% LPS removal efficacy in PBS (solid lines, Figure. 3b) by PCL NPs (1000 
μg/ml). In the case of BSA and TTZ in water, the % LPS removal dropped from 95% to ~ 
80% with the increment in protein concentrations. This reduction of LPS binding on PCL 
NPs at high protein concentrations in water could be either due to: (i) exchange of low 
affinity of the highly abundant protein binding with the NP surface by the lower 
abundance of LPS with a higher affinity for the NP surface; and/or (ii) formation of large 
aggregates between LPS-protein molecules desorbing LPS from the NP surface. In PBS, 
the % LPS removal from protein solutions was higher than that in water presumably due 
to more stable LPS-PCL NP complex formation surrounded by ions in bulk solution. On 
a preparative scale, an important indicator of desirable properties from such NP 
adsorbents is the adsorption capacity per unit mass. For this purpose, the equilibrium LPS 
adsorption capacity of PCL NPs was calculated up to 1.4 × 10଺ 𝐸𝑈/𝑚𝑔 with ~100% 
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LPS removal capacity from BSA, TTZ, fibrinogen and human hemoglobin solutions in 





Figure 3. The LPS removal efficiency of PCL NPs from protein solutions. (a) Increasing 
LPS or (b) protein concentrations have no significant effect on the % of LPS removal 
from protein solutions prepared in water and PBS. Symbols ● , ○, ∎, ▲ ,♦ indicate LPS 
containing BSA solutions in PBS, BSA in water, trastuzumab (TTZ) solutions in PBS, 
TTZ in water, Fibrinogen in PBS and Human hemoglobin in PBS respectively. 
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3.3. LPS ADSORPTION BEHAVIOR ON PCL NPs 
Based on the experimental data of LPS binding on PCL NPs, binding-dependent 
parameters were calculated using the Freundlich isotherm model that rationalizes the 
contribution of favorable adsorption on the NP surface. The experimental data fit the 
Freundlich model (R2 >0.98) where the slope ଵ
௡
  accounts for the intensity of adsorption 
and intercept, 𝐾 measures the binding affinity (μg LPS/mg PCL NPs) (Figure. 4). 𝑛 > 1 
represents favorable adsorption associated with multilayer LPS formation on the PCL 
surface.73,74 From Table S7, it can be seen that the binding intensity (n) values vary from 
1.1 – 1.4 thus indicating that the NPs have favorable LPS binding adsorption 
performance for all tested conditions.75 The binding affinity constant, 𝐾 was found to 
vary between 9.5 – 11.7 μg LPS/mg PCL NPs (~ 105-106 EU/mg) depending on the 
solution (water and PBS) and protein types (BSA and TTZ). The 𝐾 values were 
compared with previously reported sorbents76-79 which indicated that PCL NPs were 10 to 
40 log orders of magnitude better in LPS binding capacity than most of the commonly 
used adsorbents such as Polymyxin B conjugated cellulose microspheres and Histidine 
immobilized silica gels, among others.76-79 To ease out the interactions between LPS and 
PCL NPs, the NPs were coated with a cationic polymer, PLL (Figure S5). The PLL 
coated PCL NPs showed a significant decrease in % LPS removal from 80% to 60% in 
water and from 100% to 20% in PBS. These findings reassert the selective hydrophobic 




Figure 4. Freundlich adsorption isotherm fitting of LPS removal by PCL NPs from BSA 
and TTZ solutions in water and PBS. 
3.4. PROTEIN RECOVERY 
Most biopharmaceutical purification processes suffer from product loss. Protein 
recovery is as important as LPS removal to reflect an interaction of the protein with LPS 
binding sites. Figure. 5 shows the results of protein recovery at varying (a) LPS and (b) 
protein concentrations. As it is seen that protein recoveries were close to 100% for a wide 
range of LPS (0 – 160 μg/ml) and protein (0 – 1000 μg/ml) concentrations. These results 
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Figure 5. Percentage of protein recovery as a function of (a) protein concentrations and 






Figure 5. Percentage of protein recovery as a function of (a) protein concentrations and 
(b) LPS concentrations. The amount of PCL NPs used was 1000 μg/ml (cont.). 
3.5. EFFECT OF pH ON LPS REMOVAL IN DIFFERENT BUFFER 
CONDITIONS 
The percentage of LPS removal was predicted to be dependent on the changes in 
buffer pH (Figure. 6a). LPS binding on PCL NPs show reasonably strong dependence on 
pH for different buffers of variable pHs. The ionic strength for all buffers was maintained 
constant at 100 mM (0.1 M). At the pH of 2.8, i.e., near and below the isoelectric point 
(pI 2) of LPS,80 the binding of LPS with PCL NPs increased close to ~90% possibly due 
to low LPS solubility near the pI and high hydrophobic interactions between non-polar 
LPS and PCL resulting in increased LPS removal from the solution. On the other hand 
above the pI of LPS, at pHs between 5.8 and 8, average LPS removal efficiencies were 
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found to be increased from 30% up to 90% in an alkaline buffer pH of 9.6. The 
enhancement in LPS removal at high pH is most likely due to hydrophobic interactions 
between non-polar LPS and PCL NPs that segregate the polar ions and water molecules 
and minimizes the area of contact between polar and nonpolar molecules in the 
solution.81 The phase separation of LPS was further enhanced up to ~99% by PBS of 
higher ionic strength (0.15 M, pH 7.4) driving the self-assembly of LPS-PCL NP 
hydrophobic effects. In summary, PCL NPs can operate in acidic to neutral conditions 
(pH 2.8 to pH 9.6). The highest LPS removal (~100%) was found in PBS of pH 7.4 




Figure 6. The effects of pH and salt concentrations on LPS removal by PCL NPs. (a) The 
effect of pH and buffers on the % LPS removal. Four different types of buffers (acetic 
acid, phosphate, PBS and sodium bicarbonate) covering pH range from 2.8-9.6 were 
used. (b) Dependence of protein recovery on salt concentrations in LPS and PCL NP 
systems. Solid line with filled, solid circles (●) represents BSA and the dotted line with 
filled, solid squares (∎) indicates TTZ. 
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Figure 6. The effects of pH and salt concentrations on LPS removal by PCL NPs. (a) The 
effect of pH and buffers on the % LPS removal. Four different types of buffers (acetic 
acid, phosphate, PBS and sodium bicarbonate) covering pH range from 2.8-9.6 were 
used. (b) Dependence of protein recovery on salt concentrations in LPS and PCL NP 
systems. Solid line with filled, solid circles (●) represents BSA and the dotted line with 
filled, solid squares (∎) indicates TTZ (cont.). 
3.6. EFFECT OF SALT CONCENTRATION ON PROTEIN RECOVERY 
Figure. 6b shows that the % protein recovery is almost linear that varies between 
90 to 100% with the change in salt concentrations indicating that the ionic strength has a 
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little effect on protein recovery in our LPS-PCL NP system. At low salt concentrations 
extrapolated from zero salt concentration (water), the recovery was >90% for both BSA 
and TTZ which were increased further up to ~100% at higher salt concentrations (150 
mM). These results indicate that the low affinity of proteins towards PCL NPs both in the 
absence and presence of solution ions. The mutual interactions between LPS and PCL 
NPs keep protein away in the bulk phase. At higher ionic strength, it is possible that free 
ions rearrange themselves into certain configuration around LPS-PCL NP complexes and 
proteins that promote increased retention of proteins in the mixture and thus slightly 
decrease the protein recovery to ~95%. 
3.7. PCL NPs WERE REGENERATED TO REMOVE LPS 
PCL NPs were regenerated by breaking LPS-PCL complexes in RO water which 
makes the LPS removal process more efficient and scalable (Figure. 7). NaOH was used 
to regenerate the PCL NPs that exchanged off LPS for the hydroxide (𝑂𝐻ିଵ) ion in the 
caustic solution which is well-known to desorb LPS from chromatography resins and 
particles quite effectively.82-84 The collected PCL NPs were re-dissolved off the (𝑂𝐻ିଵ)  , 
and this is facilitated by the 2 h contact time. A high LPS (EU/ml) recovery (~80%) was 
observed over the course of three regeneration cycles. An average LPS recovery of  > 2 ×
10଺ EU/ml was obtained per regeneration cycle when LPS bound PCL particles were 
reacted with 0.2 N NaOH for 2 h and then washed using RO water before being reused 
for LPS binding again. Overall, the LPS removal efficiency of PCL NPs nearly had any 





Figure 7. PCL NP regeneration. LPS removal efficiency after PCL NPs is regenerated 
three times by desorbing LPS from the NPs using 0.2 N NaOH and testing for LPS 
adsorption/removal. 
3.8. PCL NPs WERE EMBEDDED IN CA MEMBRANES 
The cross-sections of CA membranes were obtained by SEM (Figure. 8a) and 
compared with and without NPs. The original CA membrane exhibited a thickness of 116 
± 2 μm and a relatively homogeneous macrostructure with a distinctive dense layer near 
the surface (Figure. 8a). Simply from the point of view of the ratio (~100) between the 
membrane thickness and the particle diameter, the presence of PCL NPs could be 
expected to have a great impact on the structural and transport properties of the 
membrane. Indeed, the CA membrane with PCL NPs showed a seemingly more uniform 
cross-sectional structure with no unique layer (Figure. 8b), which was revealed 
fluorescence microscopy to contain green dye-labeled spherical PCL particles on the flat 
surface of the membrane (Figure. 8c). The cavities in the PCL embedded membrane were 
found to be noticeably larger than those in the original CA membrane as visualized from 
the SEM images of their cross-sections (Figures. 8a and 8b). While the incorporation of 
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PCL NPs in the membrane appeared not to affect the pore opening size as there was only 
a slight change from 0.16 ± 0.05 μm to 0.17 ± 0.05 μm (Figure. S6), it has much greater 
impact on the membrane’s macro-void cross-sectional morphology as it changed from a 
narrow, tortuous, and flaky pore structure (Figure. 8a) to a broad, straight, and finger-like 
pore structure (Figure. 8b).63,85-90 PCL NPs also increased the membrane thickness by 
more than 13%, from 116 ± 403 2 μm to 132 ± 12 μm (Table S8). 
(a) 
 
Figure 8. Characterization of PCL NP embedded filter. SEM images of the cross-sections 
of membranes prepared from (a) CA membrane, scale bar = 100 μm, (b) CA membrane 
with PCL NPs in low magnification, scale bar = 100 μm and (c) Fluorescence 








Figure 8. Characterization of PCL NP embedded filter. SEM images of the cross-sections 
of membranes prepared from (a) CA membrane, scale bar = 100 μm, (b) CA membrane 
with PCL NPs in low magnification, scale bar = 100 μm and (c) Fluorescence 





3.9. PERMEATION OF WATER USING CA MEMBRANES WITHOUT AND 
WITH PCL NPs 
The measurement of water flux driven by gravity-flow through CA membrane 
was illustrated in Figure. S4, which did not require any pumping equipment or any 
vacuum driven setup other than gravity. The permeation water fluxes were approximately 
25 and 17 ௅
௠మ.௛
 at the end of 1 h through the CA membranes without and with PCL NPs, 
respectively, and reduced to 15 and 11 ௅
௠మ.௛
 , respectively, at the end of 8 h of operation 
(Figure. 9a). These results were in agreement with previously reported values.91-93 
Although the incorporation of PCL NPs appeared to create larger in size pores in the 
membrane structure (Figures 9a and 9b) that could be favorable for water to flow 
through, it also increased the membrane thickness and hence the overall mass transfer 
resistance to water flow quite significantly, which may explain the resultant lower 
permeation fluxes. In addition, the presence of NPs occupying the pore space could also 
have a similar effect by resulting in significantly narrowed passageways for water flow. 
When LPS was mixed with water, the water fluxes were observed to be lowered as well 
(Figure. 9b). Specifically, the LPS containing water fluxes at the end of 1 h and 8 h were 
reduced to ~5.4 and ~2.5 ௅
௠మ.௛
 using the original CA membrane, and ~4.2 and ~2.2 
௅
௠మ.௛
 using the CA membrane embedded with PCL NPs. There could be a number of 
factors contributing to this phenomenon, which were considered not within the scope of 
this work but worthy of future studies. For example, the binding of LPS, being large 
elongated molecules, to the surfaces of the pores and PCL NPs could significantly reduce 
the pore sizes for water flow. The addition of LPS also changed the mass density of the 
solution which would certainly affect the gravity-driven flow through the membrane. 
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These factors can be pursued in the future in order to obtain a deeper understanding and 
enable further optimization of the membrane pore structure for achieving even greater 
processability of the LPS-containing solutions. 
(a) 
 
Figure 9. Water flux performance of CA and PCL impregnated CA membrane. The water 
flux performance of CA membrane (open circles; ○) and CA membrane impregnated 
with PCL NPs (filled, solid circles; ●) (a) in the absence of LPS and (b) in the presence 
of LPS. The flow rates were measured under gravity. Error bars represent standard 
deviations from three independent experiments. * and ** indicates p values of 0.03 and 
0.01, respectively, representing statistically significant differences between the CA 





Figure 9. Water flux performance of CA and PCL impregnated CA membrane. The water 
flux performance of CA membrane (open circles; ○) and CA membrane impregnated 
with PCL NPs (filled, solid circles; ●) (a) in the absence of LPS and (b) in the presence 
of LPS. The flow rates were measured under gravity. Error bars represent standard 
deviations from three independent experiments. * and ** indicates p values of 0.03 and 
0.01, respectively, representing statistically significant differences between the CA 
membrane and PCL NPs in CA membrane (cont.). 
3.10. CA MEMBRANES WITHOUT AND WITH PCL NPs FOR REMOVING LPS 
FROM WATER 
To confirm the adsorption capability of PCL NPs in a membrane form for 
potential application in larger scale operations, the LPS removal efficiencies by the CA 
membranes with or without PCL NPs were measured and compared. As can be seen in 
Figure. 10a, the incorporation of PCL NPs in membrane significantly boosted the LPS 
removal efficiency from ~48% to ~75% at the end of 1 h, and from 88% to near 
completion at the end of 8 h. The specific endotoxin units (EU) removed were further 
calculated and compared in Figure. 10b and Table S9, which clearly demonstrated the 
superior performance of PCL NPs in the membrane as compared to its pristine powder 
form. The removal efficiency per unit area was ~4.3 × 10ସ EU/cm2 (~2.8 × 10଺ EU/mg 
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of PCL NPs) which was 2-fold (p<0.005) higher than that of NPs alone (Table S9). These 
results indicate a promising avenue for removing LPS without the requirement of any 
pumping devices or external power sources through the utilization of PCL NPs both in 
powder and membrane forms. 
(a) 
 
Figure 10. The LPS removal efficiency of PCL NP embedded filters. (a) Efficacy tests of 
CA membrane (open circles; ○) and CA membrane with PCL NPs (filled, solid circles; 
●) for the removal of LPS from the water. 𝐶଴ = 270
ఓ௚
௠௟
 𝐿𝑃𝑆 and PCL dose≈
1670 𝜇𝑔/𝑐𝑚ଶof membrane. *, ** and *** indicate p values of 0.03, 0.01 and less than 
0.005 respectively, demonstrating statistically significant differences between PCL NPs 
in CA membrane and CA membrane. (b) Bar plot of LPS removed (EU) / mg of PCL 
NPs in powder form and also in CA membrane. The extent of error bar for PCL NPs in 
CA membrane is small due to the fact that the percentage LPS removal reached ~100 %. 






Figure 10. The LPS removal efficiency of PCL NP embedded filters. (a) Efficacy tests of 
CA membrane (open circles; ○) and CA membrane with PCL NPs (filled, solid circles; 
●) for the removal of LPS from the water. 𝐶଴ = 270
ఓ௚
௠௟
 𝐿𝑃𝑆 and PCL dose≈
1670 𝜇𝑔/𝑐𝑚ଶof membrane. *, ** and *** indicate p values of 0.03, 0.01 and less than 
0.005 respectively, demonstrating statistically significant differences between PCL NPs 
in CA membrane and CA membrane. (b) Bar plot of LPS removed (EU) / mg of PCL 
NPs in powder form and also in CA membrane. The extent of error bar for PCL NPs in 
CA membrane is small due to the fact that the percentage LPS removal reached ~100 %. 
The difference between PCL NPs in powder and in the membrane is statistically 
significant (p<0.05) (cont.). 
3.11. PRODUCT COMPARISON 
PCL NPs and PCL NP retaining membranes were compared against five 
commercially available endotoxin removal products (Figure. 11 and Table I) following 
the manufacturers’ instructions. A neutral pH 7.4 PBS solution containing ~2.8 × 10଺ 
EU/ml of endotoxin was loaded in the presence of each product to determine the LPS 
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clearance and protein recovery. PCL NPs and membranes showed 1.25 to 30-fold higher 
efficiency than other commercially available products. 
 
Figure 11. Endotoxin removal product comparison. PCL NPs show higher LPS binding 
capacity as well as higher protein recovery than five commercially available endotoxin 
removal products. 
Table 1. Comparison of PCL NPs and the NP containing membrane versus four 






Relatively few polymers have been investigated for their potential to be 
synthesized into NP adsorbents for LPS removal. On a preparative scale, an important 
indicator of desirable properties from such NP adsorbents is the adsorption capacity per 
unit mass. In this work, the equilibrium adsorption capacity of PCL NPs in powder form 
and in the membrane was found to be more than 2.8 × 10଺ 𝐸𝑈/𝑚𝑔 of NPs as shown in 
Tables S2-S6 and Table S9. Previously, polymyxin B cross-linked cellulose porous 
microspheres of ~150 μm in diameter have been shown to have a maximum adsorption 
capacity of 3.6 × 10଺ 𝐸𝑈/𝑚𝑔.77 These porous beads, despite offering a high internal 
surface area for LPS adsorption, also present hindered intraparticle mass transport within 
their porous structure so that their use in a membrane or in a chromatographic column 
requires a large pressure drop.94 One way to circumvent this challenging issue of high 
pressure drop associated with high internal adsorption capacity is to use a nonporous 
solid adsorbent particle that has sufficient capacity on the exterior surface to achieve high 
adsorption efficiency at short residence time and under low pressure drop. As a type of 
such desirable adsorbent particles, PCL NPs of ~780 nm in diameter have a BET specific 
area of ≈ 6.5 𝑚ଶ/𝑔 that provides 82–98% LPS removal efficiency in water and PBS. 
These data are comparable to other previously reported processes46,77,79 and indicative of 
the potential of PCL NPs to fill the gap as a suitable adsorbent for LPS removal. 
The extent of LPS removal was found in previous studies to depend on the 
characteristics of the buffer solution, including salt concentration and pH. Increasing the 
ionic strength was found to enhance the LPS adsorption on Q-sepharose gel column.67 
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The LPS adsorption levels were 10ଶ and 10ଷ EU/ml in 10 and 50 mM PBS, 
respectively.67 Similar high LPS binding properties were shown by hydroxyapatite, 
polystyrene, Dowex 1-X2, activated charcoal, phenyland octyl-sepharose in presence of a 
high concentration of ammonium sulfate salts.69 Our PCL NPs were found to remove 
more than 10଺ EU/ml using 150 mM PBS containing 137 mM NaCl (Figures 2 –5), 
which represents an adsorption level almost 1000 fold higher than those of the previously 
published results. The effects of pH (protons) are also contingent on the electrostatic 
properties of the adsorbents.68,95 In this work, the adsorption driving forces between the 
generally hydrophobic PCL NPs (adsorbent) and LPS (adsorbate) are dominated by the 
van der Waals interactions and hydrophobic binding, which are further enhanced by 
increasing pH that weakens the repulsion between the adsorbent and the adsorbate as 
both possess partially negatively charged moieties. The enhancement in LPS binding to 
hydrophobic PCL surface can be attributed to the weakening of the shielding effect 
common with water molecules which cannot wet the hydrophobic surface and instead 
form highly ordered shell-like structure or shield around the hydrophobic surface due to 
its inability to form hydrogen bonds in all directions, thus enhancing the interaction 
between two hydrophobic surfaces (LPS and PCL).66-71 
Combinedly, our results suggest that the highly effective LPS separation could be 
due to synergistic van der Waals and hydrophobic-hydrophobic interactions driving the 
selective LPS binding with the PCL NP surface. The hydrophobic interaction of LPS 
lipid tails with PCL NPs allows recruitment and assembly of LPS molecules on the NP 
surface. This process is synergized further due to the hydration of LPS polar head groups 
by the partially positively charged hydrogen ions of water. When LPS and PCL NPs are 
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introduced to a protein solution, water molecules may rearrange by forming hydrogen 
bonds surrounding the LPS-PCL nanoparticle complex shell, thus effectively secluding 
the access of proteins to the particles. Because of this unstable nature of partial hydrogen 
ion plane surrounding the LPS-PCL NP complexes as well as individual observations, a 
wide variation in standard deviation was measured in water. In contrast, the presence of 
lyotropic salts like sodium chloride in PBS interacts strongly with these water molecules 
thus leaving less water available for the shielding effect to take place. 
The effect of different buffers at variable pH’s and constant ionic strength was 
investigated (Figure. 6). Isoelectric point for LPS is at pH 2, hence LPS is negatively 
charged at pH > 2.80 PCL NPs, on the other hand, has an isoelectric point at around pH 4 
96 and thus are positively charged at pH< 4 and negatively charged for pHs> 4. At pH 2.8 
(acetic acid buffer), LPS would be negatively charged and PCL will have a positive 
charge, hence in addition to strong hydrophobic and van der Waals interaction, ionic 
interaction contributes towards LPS binding on PCL and thus a high LPS removal of ~90 
% was observed. The presence of acetate ion (CH3COO-) which is a lyotrope also helps 
in enhancing or promoting the hydrophobic interaction even further. As the buffer pH 
increases greater than 4, both PCL NPs and LPS exhibit negative charges due to their 
carbonyl and phosphate groups respectively. Based on these results, it can be concluded 
that in case of phosphate buffer (pH 5.8-8) the repulsion between LPS and PCL NPs 
dominates the hydrophobic and van der Waals interactions and therefore results in 
reasonably low LPS removal efficiency varying between 30-75%. For sodium 
bicarbonate buffer (pH 9.6), there was a sharp rise in LPS removal efficiency up to 
~90%, indicating that the hydrophobic and van der Waals interaction dominates the 
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repulsion action between PCL and LPS molecules at high pH. One major advantage of 
the biocompatible PCL particles is that they can be reused for LPS binding quite 
effectively without a major loss in binding efficiency (Figure. 7). 
The LPS removal efficiency is further increased when PCL NPs were 
incorporated into a CA membrane, resulting in an adsorptive membrane that delivers a 
productivity flowrate of up to 25 ௅
௠మ.௛
 (Figure. 9a and 9b).97 The porous CA membrane 
structure (Figure. 8a) has a small thickness (Table S6) and a favorable pore size 
distribution to not require high pressure drops for water flow across the membrane. 
Further insight in this respect can be obtained from an analogy using the Hagen-
Poiseuille equation, 







    7  
 
where the pressure difference (∆𝑃) can be related to  𝜇 = 𝑣𝑖𝑠𝑐𝑜𝑡𝑦 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 =  8.9 ×
10ିସ𝑃𝑎. 𝑠, 𝐿 = membrane thickness = 130 × 10ି଺𝑚, 𝑞 = 𝑣𝑜𝑙𝑢𝑚𝑒𝑡𝑟𝑖𝑐 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 =
25 ௅
௠మ.௛
= 6.9 × 10ି଺𝑚/𝑠 and 𝑎 = 𝑝𝑜𝑟𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 = 0.17 × 10ି଺𝑚. The resultant ∆𝑃 
is equivalent to a low value of 63 Pa, which confirms the unnecessity of any pumping 
device for the solution to pass through the membrane to allow the adsorption removal of 
LPS to take place on the inside by the PCL NPs.  
 It is worth mentioning here that one direction for future study is to optimize the 
membrane pore structure to achieve higher productivity flowrates without sacrificing the 
loading and adsorption capability of PCL NPs. Some possibilities98 in this regard could 
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result from using more branched cellulose polymers, additives or cross-linkers, and 
templated casting surface. In addition, a very preliminary cost analysis was performed 
(Table I) to get an idea of the costs associated with manufacturing the PCL NP embedded 
CA membrane. The result was acceptably less than a dollar per cm2 . However, more 
extensive and rigorous analysis is needed when an actual process is being designed or in 
operation, which needs to take into account labor, utilities, storage, and other process 




In this study, we report first the synthesis of polymeric PCL NPs by employing a 
solvent evaporation method and then the performances of PCL NPs for the adsorption 
and removal of LPS. It was found that PCL NPs in powder form removed around 88% of 
LPS from the water sample. The presence of salts via the addition of PBS increased the 
LPS removal efficiency further up to 100% by PCL NPs, while maintaining 100% protein 
recovery from solutions. This high removal efficiency of LPS from water and PBS 
attributed to strong hydrophobic and van der Waals interaction. Buffers of variable pH 
play a very important role in determining the LPS binding on PCL. Acidic (pH 2.8) and 
alkaline (pH 9.6) buffers give ~ 90% LPS removal whereas intermediate pHs from 5.8 to 
8 give reasonably lower % LPS removal between 30-75%. The adsorption efficiency 
reached almost 100% when PCL NPs were incorporated into the CA membrane where 
the water flow through the porous structure was directly by gravity without the 
requirement of any pumping devices. The biocompatible PCL NPs can be reused by 
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desorbing majority of adsorbed LPS using 0.2 N NaOH solution. A preliminary cost 
analysis showed that the manufacturing cost of the PCL NP embedded CA membrane is 
quite affordable. These findings coupled with PCL NP’s known biodegradability support 
the potential of hybrid NP-membrane system to be used in large-scale operations that 
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Figure S1. A standard curve to determine the optimum mass ratio of BODIPY : LPS 
interaction at different concentrations of LPS. BODIPY concentration was 262.11µg/ml. 
Addition of LPS to BODIPY results in quenching due to binding of LPS to BODIPY 
sites. The binding saturates at 150 µg/ml endotoxin concentration. The optimum ratio of 




Figure S2. To confirm the linear correlation of the BODIPY assay standard curve for LPS 
detection (Figure S1) within the range of 0-50 g/ml, the calibration curve was 
regenerated independently over the range of interest. (a) The BODIPY assay standard 
curve indeed shows a linear relationship at this low LPS concentration range. We further 
tested this new standard curve to calculate % LPS removal using LPS feed concentrations 
between 0-50 g/ml. (b) The % LPS removal calculated using the correlation shown in 
(a). (c) The % LPS removal (solid circles) was compared with the values generated using 
Figure S1(open circles) as shown in Figure 2 (b) in the main texts. The values from two 
independently generated standard curves were found to be evenly distributed and fit 

















y = 795.81x   R2= 0.99709 
y = 780.45x   R2= 0.99531 
y = 781.48x   R2= 0.99124 
y = 827.02x   R2= 0.9983 
y = 918.25x   R2= 0.98703 















 Absorbance @ 562 nm
Figure S3. Protein standard curves of BSA and Trastuzumab (TTZ; Genentech) in water 
and PBS (pH 7.4) and Fibrinogen and Human hemoglobin in PBS (pH 7.4) were used to 
measure protein concentrations. R2 represents the regression value. 
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Figure S4. Experimental set up of a custom-made PVC column to sandwich CA 
membrane without and with PCL NPs in between two flow pipes. A piece of membrane 
was screw tightened between two flow pipes (top and bottom). Water and LPS containing 
water was fed on the top PVC pipe and let it flow by gravity. The permeability of 
membrane and % LPS removal were assessed using this set-up. 
Table S2. The LPS binding capacity, endotoxin unit (EU) removed by per surface area 




Table S3. The LPS binding capacity (EU/cm2 and EU/mg) by PCL NPs from varying 
BSA concentrations in PBS (pH 7.4) when treated with a fixed concentration of LPS (150 
g/ml  1.5 × 10଺ EU/ml). 1 EU≈ 0.1 – 0.2 𝑛𝑔 of LPS. 
 
Table S4. LPS binding capacity (EU/cm2 and EU/mg) by PCL NPs from varying 
Trastuzumab concentrations in PBS (pH 7.4) when treated with a fixed concentration of 





Table S5. LPS binding capacity (EU/cm2 and EU/mg) by PCL NPs from varying 
Fibrinogen concentrations in PBS (pH 7.4) when treated with a fixed concentration of 
LPS (150 g/ml  1.5 × 10଺ EU/ml). 
 
Table S6. LPS binding capacity (EU/cm2 and EU/mg) by PCL NPs from varying Human 
hemoglobin concentrations in PBS (pH 7.4) when treated with a fixed concentration of 
















Figure S5. Zeta potential and LPS removal efficiency of poly-l-lysine (PLL) coated PCL 
NPs. (a) The surface zeta potential of positively charged PLL coated PCL NPs which 
confirmed the clear shift in surface charge towards (10 ± 0.3) mV from (-20 ± 5) mV of 
bare PCL NPs (Figure 1(c)). (b) The PLL coated PCL NPs showed ~20 and 80% 
reduction in % LPS removal in water and PBS, respectively compared to bare PCL NPs 
indicating the cationic charges on the surface of PCL NPs decreased the interaction of 





Figure S6. Surface SEM morphology of CA membrane (a) without and (b) with PCL 
NPs. 
Table S8. Calculations of CA membrane thickness and pore size with and without PCL 
NPs. 
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ABSTRACT 
Endotoxin removal from therapeutic solutions is a challenging task for the 
biopharmaceutical industries. Currently, approximately one- third of all therapeutics are 
produced from biological sources like Escherichia coli and Salmonella. In addition to the 
useful bio therapeutics these E. coli cells also release endotoxins in the surrounding 
media thus contaminating the life-saving therapeutics. Hence, these therapeutic products 
need to be thoroughly purified before being used for any parenteral applications. It was 
demonstrated that biocompatible polymeric PCL NPs (𝑑௉~ 800 𝑛𝑚) were effective in 
removing endotoxins from aqueous solutions with a removal efficiency ~ 98 % in 
phosphate buffer saline (PBS) and protein recovery of ~ 100 %. The goal of this work 
was to test the validity of the hypothesis that synergistic combination of van der Waals 
and hydrophobic interactions were responsible for endotoxin binding on 
polycaprolactone (PCL) nanoparticle’s (NPs) surface.  This hypothesis was tested by 
evaluating endotoxin removal efficiency of a material which shows surface 
hydrophobicity similar to that of PCL NPs. Polystyrene (PS) nanoparticles,~ 800 𝑛𝑚, 
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with surface properties similar to PCL NPs were used as a control to test the hypothesis.  
Additionally, this work demonstrated that acidic (pH 2.8) and basic (pH 11.5) 
conditions do not have a major impact on protein recovery using PCL NPs. Six 
different types of proteins with molecular weights varying from 14 kDa - 341 kDa and 
isoelectric points (pI) from 4.5-10.7 showed protein recovery > 92 % under extreme 
operating pH. Finally, in order to increase the throughput and address the mass transfer 
limitations, the PCL NPs incorporated cellulose acetate (CA) biofilter were synthesized 
and applied to different protein solutions with a maximum endotoxin removal efficiency 




The source of one-third of all biotherapeutics, presently, is gram-negative bacteria 
[1, 2] for example, Escherichia coli and Salmonella. Endotoxins are the primary and most 
toxic components located on the outer cell membrane of these gram-negative bacteria.[3-8] 
As a result, while extracting biotherapeutics from these bacteria, endotoxins also get 
tagged along.  It, therefore, requires thorough purification and polishing steps before 
being used for parenteral applications.[2,9-11] Endotoxin structure comprises polar 
heteropolysaccharide chains that are covalently bonded to the non-polar lipid-A moiety.[3-
8, 12] Lipid-A tail is responsible for anchoring and providing mechanical stability to the 
endotoxin molecule in the cell membrane. [3, 8, 12] Removing undesirable contaminants 
like endotoxins from biologically derived therapeutic products thus is a challenging task 
for biopharmaceutical engineers. Isoelectric point (pI) of endotoxin molecules is at pH 2, 
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thus in most biological solutions endotoxin structure comprises a hydrophobic lipid tail 
and a negatively charged phosphate group. Therefore, both ionic[7, 13-17] (ion exchange 
chromatography) and hydrophobic interactions[18, 19] (hydrophobic interaction 
chromatography) are widely utilized to bind and remove endotoxins from biological 
solutions. Endotoxin binding mechanism on the ligand surface is dependent on the ionic 
strength of the liquid media. In liquid media with low high ionic strength binding is 
mainly dominated by charge based ionic interaction which weakens in presence of salt 
ions. On the other hand, in conditions of higher ionic strength (PBS; 150 mM), 
interactions driven by hydrophobicity and van der Waals binding are more impactful.[20]   
In literature different types of interactions have been highlighted to remove 
endotoxins from biological solutions. For example, bare polymeric nanoparticles and 
adsorbent crystals like polycaprolactone nanoparticles (PCL NPs)[21] and allantoin[22] 
(2,5-dioxo-4-imidazolidinyl urea) have shown high endotoxin removal efficiency of > 98 
%. These adsorbents also provide high protein recovery of > 92 % and ~ 80 % 
respectively, hence making these a viable alternative to remove endotoxins from protein 
solutions. PCL NPs have been reported to utilize van der Waals and hydrophobic 
interactions[21] to bind endotoxins whereas endotoxin binding on allantoin surface is 
mediated by hydrogen bonding.[22] In addition to the bare particles, different types of 
endotoxin-selective ligands have been grafted, immobilized or coated on the surface of 
metallic or polymeric matrices to devise a viable endotoxin binding material. For 
example, chitosan-iron oxide nanocomposites have also been very effective at binding 
negatively charged endotoxins from various protein solutions due to their positive charge 
from chitosan.[12]It provides an endotoxin removal of  > 99 % and a protein recovery > 90 
  
107
%.[12] Polymyxin-B is another such ligand which finds widespread application in 
endotoxin binding. Polymyxin-B coated silver nanoparticles have been shown to remove 
> 97 % endotoxins from aqueous solutions.[23] These coated silver particles utilize ionic 
interaction between the phosphate ion on endotoxin and cationic peptide on polymyxin-
B. Polymyxin-B with other ligands like polyethyleneimine (PEI), histamine and 
tetracaine have been used to modify surface of polystyrene core and polyglycidyl 
methacrylate shell based polymeric nanoparticles to use these as an endotoxin binding 
material.[20] The modified nanoparticles have been shown to have an endotoxin removal 
efficiency of around 90 % from water and salt solutions. They utilize van der Waals, 
hydrophobic and ionic interactions to bind endotoxin on their surface. Additionally, 
grafting of long carbon chain on nanoparticle surface to induce hydrophobicity has also 
been utilized in many cases. One such system comprised of long C18 acyl chains 
attached to Fe3O4/Au/Fe3O4 nanoflowers (NFs). These NFs utilize hydrophobic 
interaction between the lipid-A part and C-18 chains to carry out endotoxin removal 
effectively.[24]   
Even though porous resins (with or without ligands) based techniques are 
effective at binding and removing endotoxin from biological solutions they suffer from 
various drawbacks like, high pressure drop, poor mass transfer, clogging and pore 
structure damage.[25, 26] Hence, downstream purification operation with these materials is 
expensive and inconvenient. Also, Polymyxin-B and histamine immobilized resins can 
lead to neurotoxicity and nephrotoxicity.[3, 6-8, 27] To address these drawbacks, non-porous 
and biocompatible PCL NPs (𝑑௉~ 800 𝑛𝑚) were synthesized for binding endotoxin on 
their surface.[21] The present work attempts  to test the validity of the hypothesis that van 
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der Waals and hydrophobic interactions are responsible for endotoxin binding on the 
hydrophobic surface. To test the hypothesis, a model polymer, polystyrene nanoparticles 
with hydrophobic surface similar to that of PCL NPs are used as a control. In addition, 
the effect of extreme pH conditions on protein recoveries has also been investigated. 
Also, the paper extends the application of PCL NPs incorporated cellulose acetate (CA) 
biofilter in removing endotoxins from protein solutions. The biofilter combine the 
advantages of both PCL NPs and thin sheet flat filters for improved binding and flow 
properties at a reduced cost with higher throughput. 
 
2. MATERIALS AND METHODS 
2.1. SYNTHESIS OF BARE PCL AND MODIFIED PCL NANOPARTICLES 
Bare PCL NPs were synthesized using the solvent evaporation technique which 
utilized high–speed homogenization and sonication, followed by solvent evaporation, 
centrifugation to remove surfactants, and finally freeze-drying to remove water.[21, 28-32] A 
preformed polycaprolactone (PCL) polymer solution in ethyl acetate at a concentration of 
10 mg/ml was injected using a syringe pump to a 1% w/v polyvinyl alcohol (PVA) 
solution prepared with reverse osmosis (RO) water. The mixture was homogenized by 
using a homogenizer rotating at 3000 rpm while being placed in a sonication bath. Ethyl 
acetate was removed by stirring the mixture at 300 rpm for two days. The obtained 
particle suspension was washed five times using RO water and centrifugation for 30 
minutes at 10,000 rcf. The resulting products were freeze-dried, weighed, and stored at 
4ºC until further use. PCL NPs surface was coated with three different cationic ligands. 
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The three ligands used were poly-L-Lysine (PLL; Sigma Aldrich), polyethylenimine 
(PEI; Sigma Aldrich) and chitosan (MP Biomedicals).[33] To coat the surface of bare PCL 
NPs,  10 mg of freeze dried PCL NPs were incubated with 1 ml of  50 µg/ml solution of 
these ligands for 1 h. Post incubation the particle suspension was centrifuged for 30 min 
at 16,000 rcf and the supernatant was separated. Subsequently, the ligand-coated 
nanoparticles were washed with RO water five times and the particles freeze-dried to 
obtain positively charged and modified PCL NPs. 
2.2. CHARACTERIZATION OF BARE PCL AND MODIFIED PCL 
NANOPARTICLES 
The surface morphology, topology and geometry of PCL NPs were observed 
using Hitachi S-4700 scanning electron microscope (SEM) at an accelerating voltage of 
15 kV. Samples were sputter coated with Denton Au/Pd coater before being inserted into 
the microscope. The average PCL NP size was measured by analyzing the SEM images 
using the ImageJ software (version 1.51w). The average particle size was reported as 
mean ± standard deviation (SD) based on the diameters of 200 randomly selected 
particles. The hydrodynamic size and surface charge of NPs were characterized by 
dynamic light scattering (DLS) and zeta potential (𝜁) measurements, respectively using 
Malvern NanoZS90 Zetasizer. The hydrodynamic diameter of PCL NPs was measured at 
25ºC using He-Ne Lasers at 90º scattering angle. The size distribution was obtained based 
on three independent experiments utilizing 100 successive runs. Zeta potential values 
were reported based on three independent experiments; each experiment utilizing 15 
successive runs, and the results were reported as millivolts (mV) ± SD. 
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2.3. EFFECTS OF pH ON PROTEIN RECOVERIES 
BCA assay (Thermo fisher scientific) was employed to calculate the amount of 
protein recovered after endotoxin was removed from the solution using polymeric 
particles. Six different proteins were used in the experiments, namely, ovalbumin (pI 4.5; 
Thermo fisher scientific), bovine serum albumin (BSA; pI 4.7; Thermo fisher scientific), 
fibrinogen (pI 5.8; Alfa Aesar), bovine hemoglobin (pI 7.1; Sigma Aldrich), trastuzumab 
(TTZ; pI 8.5; Genentech) and lysozyme (pI 10.7; Thermo fisher scientific). A suspension 
of PCL NPs (1000 µg/ml) and protein (1000 µg/ml) at three different pH: acidic (pH 2.8), 
pI (protein) and basic (pH 11.5) was incubated for 30 minutes under room conditions. 
Subsequently, the suspension was centrifuged for 30 min at 16,000 rcf and the 
supernatant was treated with BCA assay reagents to estimate the protein recoveries. This 
was done by comparing absorbance values at 562 nm after and before introducing PCL 
NPs using the standard curves for each protein at the given pH values (Figures. S1, S2 
and S3). The different pH values are based on recipes in (Table S1).   
2.4. EVALUATION OF CONJUGATION EFFICIENCY OF MODIFIED PCL 
NANOPARTICLES 
Conjugation efficiency of PLL, PEI and chitosan on PCL NPs was evaluated 
using the ninhydrin assay.[34, 35] To begin with, 4 M sodium hydroxide buffer with pH 5.2 
was prepared using glacial acetic acid, sodium hydroxide and water. Ninhydrin reagent 
(125 mg/ml) was prepared using dimethyl sulfoxide (DMSO) and sodium hydroxide 
buffer in 1:3 ratio. Next, to 100 µL of known standard PLL, PEI and chitosan ligand 
concentrations added 100 µL of ninhydrin reagent (Sigma Aldrich) and placed the 
centrifuge tubes in water bath at 80○ C for 30 minutes. Post water bath treatment cooled 
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the tubes down to room temperature and added 300 µL of stabilizing agent (water). 
Subsequently, poured 150 µL in triplicates from each tube into the 96 well plates and 
measured the absorbance at 570 nm for each ligand concentration. To evaluate the 
conjugation efficiency post incubation for each of the three cationic ligands (50 µg/ml), 
centrifuged the tubes at 16,000 rcf for 30 minutes and then repeated the above steps with 
100 µL of the supernatant. Percent (%) conjugation efficiency of each of the ligands can 
be evaluated using the standard curves (Figure. S4). 
2.5. EVALUATION OF ENDOTOXIN REMOVAL EFFICIENCY OF 
PARTICLES (IN RO WATER AND PBS) 
Endotoxin (Escherichia coli O111 : B4 LPS; Sigma Aldrich) removal efficiency 
of bare Polycaprolactone (PCL), modified PCL and Polystyrene (PS) NPs 
(Magsphere,Inc) of ~ 800 nm was evaluated using the Bodipy (BOD; Invitrogen) 
fluorescence displacement assay technique.[21, 32, 36] BOD is a fluorescent dye which acts 
as a lipid biomarker and quenches its fluorescence intensity (F.I) on interaction with 
endotoxin.[21, 32] The evaluation of endotoxin binding on polymeric particle surface was 
evaluated by indirectly calculating the amount of endotoxin present in the supernatant 
after incubating the endotoxin spiked aqueous solution with known PCL NPs 
concentration.[20] In these experiments, known polymer particle (PCL, modified PCL and 
PS NPs) concentration of 1000 µg/ml was incubated for 30 minutes under room 
conditions with known endotoxin concentration of 150 µg/ml in a centrifuge tube. 
Subsequently, the suspension was centrifuged for 30 min at 16,000 rcf and the 
supernatant was treated with BOD to estimate the endotoxin removal efficiency. Separate 
sets of experiments were performed in both RO water (pH ~7) and phosphate buffered 
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saline (PBS; 150 mM, pH ~7.4). The composition of PBS is as follows: 137 mM NaCl, 
10 mM phosphate, and 2.7 mM KCl at 25C. Endotoxin removal efficiency of 
polystyrene NPs was also calculated at 10X and 100X dilutions of PBS in addition to 
the PBS alone to study the effect of salt ionic strength on endotoxin removal.  
The F.I. of BOD was used to determine the endotoxin concentration in solution. 
The F.I. measurements were carried out using a microplate reader (BioTek). Excitation 
and emission wavelengths for BOD were 485/20 and 528/20 nm, respectively. RO water 
was used as a negative control. The background fluorescence intensities were subtracted 
to avoid any interferences. The percentage (%) endotoxin removal by polymeric NPs 
from water and PBS was calculated using equation (1): 
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where 𝐹𝐼஻ை஽ , 𝐹𝐼஻ை஽.ா௡ௗ, and 𝐹𝐼஻ை஽.ா௡ௗ.௉௢௟ represent the F.I. of BOD alone, BOD mixed 
with endotoxin, and BOD mixed with supernatant of polymeric NPs and endotoxin 
suspension, respectively. 
2.6. SYNTHESIS OF CELLULOSE ACETATE (CA) BIOFILTER  
Blank CA biofilter without any PCL NPs were prepared by a non-solvent induced 
phase separation process.[21, 37, 38] A casting solution was prepared by dissolving 10 wt.% 
each of CA and 5 wt.% glycerol in dimethyl sulfoxide (DMSO). For biofilter with NPs, 1 
wt.% of PCL NPs  was dispersed in the casting solution under vigorous stirring (1100 
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rpm) at 50ºC for 1 h to allow homogenous mixing and then left overnight to allow 
complete release of bubbles. The final solution was cast on a casting plate and then 
immersed in RO water coagulation bath for 30 min. Finally, the water wet biofilter was 
immersed in 30% glycerol (plasticizer) for 15 min, which in addition to improving the 
mechanical properties also helped in dry storage of the membrane for at least 300 days 
with no major loss in membrane flux and removal properties.[21, 39]  
2.7. MICROSCOPY AND MICROANALYSIS 
The CA biofilter with or without PCL NPs was dried using the freeze–fracture 
method.[40] Samples were attached to a SEM stub and sputter coated with Denton Au/Pd 
coater. The biofilter surface and cross sections were imaged using the Hitachi S-4700 
SEM operated at 3 kV. The biofilter surface and cross-sectional morphology, pore size, 
and thickness were analyzed using ImageJ software (version 1.51w). The average 
biofilter pore size and thickness were based on 100 randomly selected pores and locations 
from different images. The results were reported as average ± standard deviation (SD). 
The incorporation of PCL NPs in the biofilter were further validated by magnifying the 
surface and cross-section of the membrane sample under consideration. 
2.8. WATER FLUX STUDIES 
The flux measurements were carried out using custom-made biofilter testing 
experimental set-up. The apparatus comprised of two polyvinyl chloride (PVC) pipes 
attached to blocks that sandwich the biofilter between them. Each of the PVC pipes had a 
diameter of 1.5 cm. The top half of the experimental set-up consisted of PVC pipe which 
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was 20 cm long whereas bottom half had a PVC pipe that was 10 cm long. The biofilter 
area coming in contact with the water or endotoxin spiked protein solution was 1.8 cm2. 
For each experiment the feed volume (water or endotoxin spiked protein solution) was 
kept constant at 20 ml and then allowed to pass through the biofilter under the influence 
of gravity. For endotoxin spiked protein solution the concentration of protein was kept 
constant at 1000 µg/ml and that of endotoxin was fixed at 57.4 µg/ml. The permeate 
volumes were measured at 15 minute intervals for 90 minutes duration to estimate the 
change in flux.  






  2  
                                                                                                  
where J ( ௅
௠మ௛
) is the water flux of the samples, V (L) is the volume of permeate collected 
at specific time interval, A (m2) is the biofilter contact area and t (h) is the time. 
2.9. QUANTIFICATION OF ENDOTOXIN REMOVAL USING PCL NPS IN CA 
BIOFILTER 
The determination of endotoxin removal by CA biofilter with or without PCL NPs 
was also carried out by BOD fluorescence displacement assay technique [32, 41] in the 
apparatus described above.  A volume of 20 ml protein solution (1000 µg/ml) spiked with 
57.4 g/ml of endotoxin was fed to the top flow pipe to flow through a sandwiched 
biofilter by gravity. A fixed volume 460 µL of the endotoxin spiked protein feed and 
permeate was collected every 15 minutes until 90 minutes. The samples were mixed with 
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BOD (99.99 µg/ml) and the F.I. of BOD was measured using a plate reader (BioTek). 
The percent (%) endotoxin removal was calculated using equation (3), 
        
 ,Pr ,Pr ,  in permeate
,Pr ,Pr ,  in feed
% Endotoxin (1 ) 100BOD otein BOD otein End
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where 𝐹𝐼஻ை஽,  𝐹𝐼஻ை஽.ா௡ௗ ௜௡ ௣௘௥௠௘௔௧௘, and 𝐹𝐼஻ை஽.ா௡ௗ ௜௡ ௙௘௘ௗ are the F.I.s of BOD alone, 
BOD mixed with endotoxin in permeate, and BOD mixed with endotoxin in the feed 
solution, respectively.  Each value used here were based on triplicate measurements from 
three independent experiments. The mean differences and standard deviations were also 
evaluated. 
 
3. RESULTS  
3.1. SYNTHESIS OF POLYCAPROLACTONE NANOPARTICLES   
The spherical PCL NPs were successfully prepared using the solvent evaporation 
technique. From the SEM image (Figure. 1a) and dynamic light scattering (DLS) plot 
(Figure. 1b) it is apparent that the particles were spherical and non-porous with smooth 
surface. The particle size was 760 ± 345 𝑛𝑚. Zeta potential (𝜁), of PCL NPs in water 
was −17 ± 4 𝑚𝑉 (Figure. 1c) suggesting that the particles were reasonably stable in 









Figure 1. Characterization of PCL NPs. (a) SEM image of PCL NPs at 30,000 X 
magnification. (b) Plot showing size distribution of PCL NPs. (c) Zeta potential of PCL 





Figure 1. Characterization of PCL NPs. (a) SEM image of PCL NPs at 30,000 X 
magnification. (b) Plot showing size distribution of PCL NPs. (c) Zeta potential of PCL 
NPs in water. Multiple colors indicate different independent runs (cont.). 
3.2. EFFECT OF pH ON PROTEIN RECOVERIES  
The effect of pH on protein recovery were also investigated for six different 
proteins in presence of PCL NPs. Proteins used in the experiments were: ovalbumin 
(M.W- 42.7 kDa; pI 4.5), bovine serum albumin (M.W- 66.5 kDa; BSA; pI 4.7), 
fibrinogen (M.W- 341 kDa; pI 5.8), bovine hemoglobin (M.W- 64.5 kDa; pI 7.1), 
trastuzumab (M.W- 148 kDa; TTZ; pI 8.5) and lysozyme (M.W- 14.3 kDa; pI 10.7). 
Protein recovery for each samples were evaluated at three different pH conditions: pH 
2.8, pH= isoelectric point (pI) and pH 11.5. In each set of experiments the proteins were 
water based and a fixed concentration of 1000 µg/ml was used for proteins and PCL NPs. 
At pH 2.8, all the protein samples except TTZ gave high protein recoveries > 96 % 
(Figure. 2). The protein recoveries varied between 94% for TTZ to 100 % for lysozyme. 
At pH 11.5, all the protein samples except lysozyme saw protein recoveries > 97 % 
  
118
(Figure. 2).  The protein recoveries varied between 93% for lysozyme to 100 % for 
fibrinogen and bovine hemoglobin. On performing the experiment at the pI, protein 
recoveries ~ 100 % (98-100 %) were seen for all protein samples (Figure. 2). The 
recipes to obtain the mentioned pH’s can be found in the supplementary information 
section (Table S1). 
Figure 2. The effects of pH on protein recovery using PCL NPs. The effect of pH on 
protein recoveries was evaluated at three different values: pH 2.8, isoelectric point (pI) 
and 11.5. Six different types of proteins with different pI’s and molecular weights were 
used: Ovalbumin (M.W- 42.7 kDa; pI 4.5), Bovine Serum Albumin (BSA; M.W- 66.5 
kDa; pI 4.7), Fibrinogen (Fib; M.W- 341 kDa; pI 5.8), Bovine Hemoglobin (M.W- 64.5 
kDa; pI 7.1), Trastuzumab (TTZ; M.W- 148 kDa; pI 8.5) and Lysozyme (M.W- 14.3 
kDa; pI 10.7) Particle and protein concentration were kept constant at 1000 g/ml. 
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3.3. ENDOTOXIN REMOVAL EFFICIENCY COMPARISON FROM WATER 
AND PBS USING PCL NPs AND POLYSTYRENE NPs  
As stated before PCL NPs were hypothesized to utilize synergistic combination of 
van der Waals and hydrophobic interactions to bind and remove endotoxin from 
biological solutions effectively.  Similar to PCL NPs, PS NPs also possess a hydrophobic 
surface and show binding affinity towards endotoxin, but not as high as PCL NPs. 
Endotoxin binding efficiency of PS NPs (𝑑௉~ 800 𝑛𝑚) was investigated in water and 
PBS at different dilutions. PS NPs (𝑑௉~ 800 𝑛𝑚) and endotoxin concentrations were 
fixed at 1000 µg/ml and 150 µg/ml (1.5 × 10଺  EU/ml). The endotoxin binding 
experiments were carried out in RO water, PBS and PBS at different dilutions (10X and 
100X). PS NPs endotoxin removal efficiency was ~ 31 % (4.6 × 10ହ  EU/ml) from water 
which increased to ~ 75 % (1.1 × 10଺  EU/ml) in presence of PBS (Figures. 3 and S5; 
Table S2). On diluting PBS to 10X and 100X the endotoxin binding efficiency reduced to 
45 % (6.7 × 10ହ  EU/ml) and 35 % (5.2 × 10ହ  EU/ml) respectively (Figures. 3 and S5; 
Table S2). 
3.4. CONJUGATION EFFICIENCY OF CATIONIC LIGAND ON PCL NPs 
SURFACE 
Bare PCL NPs were coated with cationic ligands to modify the surface of the PCL 
NPs. In these experiments three different cationic ligands were used to coat the PCL 
surface. Poly-L-Lysine (PLL), polyethylenimine (PEI) and chitosan solutions (50 µg/ml) 
were incubated with 10 mg PCL NPs. Conjugation efficiency for each ligand was 




Figure 3. Comparison of endotoxin removal and binding efficiency of bare PCL NPs with 
Polystyrene NPs in water and PBS. % endotoxin removal efficiency comparison of PCL 
NPs (𝑑௉~ 800 𝑛𝑚) with Polystyrene NPs (𝑑௉~ 800 𝑛𝑚) in RO water and PBS at 
different dilutions. Particle concentration was maintained constant at 1000 g/ml and 
endotoxin concentration at 150 g/ml. * indicates the p-value < 0.1 showing a statistically 
significant difference between % endotoxin removal in water and PBS. 
 The % conjugation efficiency for PLL, PEI and chitosan ligands was 70 %, 60 % 
and 71 % respectively (Figure. 4a). Subsequently, the zeta potential of modified PCL NPs 
was measured. PLL, PEI and chitosan coated PCL NPs showed a zeta potential value 
of 8 ± 4 𝑚𝑉, 12.6 ± 3 𝑚𝑉 and 1.4 ± 2 𝑚𝑉 respectively (Figures. 4b, 4c and 4d). The 
change in zeta potential values of PCL NPs (−17 ± 4 𝑚𝑉) post incubation with the 








Figure 4. % Conjugation efficiency and zeta potential of PLL, PEI and chitosan ligands 
coated PCL NPs. (a) PCL NPs were coated with cationic ligands like, PLL, PEI and 
chitosan by incubating 10 mg of particles with 1 ml of 50 g/ml ligand solution for 1 
hour. Conjugation efficiency of the ligands was evaluated using the ninhydrin assay. (b) 
Zeta potential of PLL coated PCL NPs. (c) Zeta potential of PEI coated PCL NPs. (d) 







Figure 4. % Conjugation efficiency and zeta potential of PLL, PEI and chitosan ligands 
coated PCL NPs. (a) PCL NPs were coated with cationic ligands like, PLL, PEI and 
chitosan by incubating 10 mg of particles with 1 ml of 50 g/ml ligand solution for 1 
hour. Conjugation efficiency of the ligands was evaluated using the ninhydrin assay. (b) 
Zeta potential of PLL coated PCL NPs. (c) Zeta potential of PEI coated PCL NPs. (d) 




3.5. ENDOTOXIN REMOVAL EFFICIENCY COMPARISON FROM WATER 
AND PBS USING PCL NPs AND CATIONIC LIGAND MODIFIED PCL NPs  
Endotoxin removal performance of cationic ligand modified PCL NPs was 
investigated from water and PBS (pH 7.4). For these experiments the polymer particle 
and endotoxin concentrations were maintained constant at 1000 µg/ml and 150 µg/ml 
(1.5 × 10଺  EU/ml).  The endotoxin removal efficiency varied from 10 - 32 % (1.5 ×
10ହ − 4.8 × 10ହ  EU/ml) for cationic ligand modified PCL NPs in water (Figures. 5 and 
S6; Table S3). Under the same conditions PCL NPs showed an endotoxin removal 
efficiency of ~ 82 % (1.2 × 10଺  EU/ml) which was much higher than cationic ligand 
coated particles (Figures. 5 and S6; Table S3). In presence of PBS endotoxin binding 
due to ionic interaction further weakened (Figures. 5 and S6; Table S4) as the removal 
performance of cationic ligand coated particles dropped further to 8 - 10 % (1.2 ×
10ହ − 1.4 × 10ହ  EU/ml). On comparison, PCL NPs (Figures. 5 and S6; Table S4) saw 
an upward increasing trend with a removal efficiency of ~ 98 % ( ~1.4 × 10଺  EU/ml) 
in PBS solution. 
3.6. ENDOTOXIN REMOVAL FROM PROTEIN SAMPLES USING PCL NPs 
INCORPORATED CA BIOFILTER 
PCL NPs showed good endotoxin binding efficiency from water, phosphate 
buffer saline (PBS) and therapeutics. Thus, in this work cellulose acetate (CA) biofilter 
with PCL NPs incorporated in the matrix were used to bind and remove endotoxin from 
various protein solutions. The biofilter were prepared using the non-solvent induced 




Figure 5. Comparison of endotoxin removal and binding efficiency of bare PCL NPs with 
cationic ligand modified PCL NPs in RO water and PBS. % endotoxin removal efficiency 
comparison of PCL NPs , PLL, PEI and chitosan coated PCL NPs in RO water and PBS. 
Particle concentration was maintained constant at 1000 g/ml and endotoxin 
concentration at 150 g/ml. ***, ** and * indicates the p-value < 0.01, < 0.05 and < 0.1 




Figures 6a and 6b represent the SEM image of CA biofilter and PCL incorporated 
CA biofilter. From the images it can be seen that the surface pore size of CA and PCL 
incorporated CA biofilter is 0.37 ± 0.13 m and 0.40 ± 0.12 m respectively. CA and 
PCL incorporated CA biofilter had a thickness of 117 ± 4 m and 120 ± 3 m 





Figure 6. Surface and cross-section morphology of biofilter. The SEM images represent 
the surface and cross-section morphology of two different types of biofilter: (a). Surface 
and cross-sectional morphology of cellulose acetate (CA) biofilter. Pore size and 
thickness of the biofilter were estimated based on 100 random measurements and is 0.37 
± 0.13 m and 117 ± 4 m respectively. (b). Surface and cross-sectional morphology of 
PCL NPs incorporated CA biofilter. Pore size and thickness of the biofilter were 






Figure 6. Surface and cross-section morphology of biofilter. The SEM images represent 
the surface and cross-section morphology of two different types of biofilter: (a). Surface 
and cross-sectional morphology of cellulose acetate (CA) biofilter. Pore size and 
thickness of the biofilter were estimated based on 100 random measurements and is 0.37 
± 0.13 m and 117 ± 4 m respectively. (b). Surface and cross-sectional morphology of 
PCL NPs incorporated CA biofilter. Pore size and thickness of the biofilter were 
estimated based on 100 random measurements and is 0.40 ± 0.12 m and 120 ± 3 m 
respectively (cont.). 
Water flux experiments with gravity as the driving force were carried out for both 
biofilter, with and without PCL NPs. As shown in Figure. 7a the pure water flux of CA 





lines) was approximately 200 and 150 ௅
௠మ.௛
 to begin with at the end of 15 minutes which 
reduced to 12 and 26 ௅
௠మ.௛
, respectively, at the end of 90 minutes of operation. When 
water flux measurements of protein samples spiked with endotoxins were carried out a 
drop in water flux was observed with both CA (dotted lines) and PCL incorporated CA 
biofilter (solid lines). Average water flux at the end of 15 minutes was 90 ௅
௠మ.௛
 for BSA 
(●), ovalbumin (■), bovine hemoglobin (▲), lysozyme (○) and trastuzumab (□) proteins 
when passed though the CA biofilter (Figure. 7b). The water flux value dropped to 60 
௅
௠మ.௛
 at the end of 90 minutes. On the other hand for PCL NPs incorporated CA biofilter 
the average water flux at the end of 15 minutes was 41 ௅
௠మ.௛
 (Figure. 7b) which dropped 
to 15 ௅
௠మ.௛
 at the end of 90 minutes.  
The drop in pure water, protein and endotoxin spiked water flux in biofilter with 
PCL NPs can be attributed to the resistance offered by PCL NPs incorporated within the 
matrix of the filter thus slowing down the flow. Also, resistance offered by endotoxin 
micelles (elongated structure) attached to the PCL surface within the membranes could be 
another possible reason for the drop in flux. In terms of endotoxin removal from proteins, 
we noticed a reasonably high endotoxin removal capability of CA biofilter with PCL 
NPs. During the experiment five different proteins were considered namely, bovine 
serum albumin (BSA), ovalbumin, bovine hemoglobin, trastuzumab (TTZ) and 
lysozyme. The average maximum endotoxin removal efficiency varied from 95 % (5.5 ×
10ହ  EU/ml) for TTZ to 99% (5.7 × 10ହ  EU/ml) for ovalbumin at the end of 15 minutes 








Figure 7. Water flux though CA and PCL incorporated CA biofilter. (a)Water flux plot 
for 90 minute duration using CA (open circles, ○; dotted line) and PCL incorporated CA 
biofilter (filled, solid circles, ●; solid line). * and ** indicates p values of < 0.1 and < 
0.05, respectively, representing statistically significant differences between the water flux 
of CA biofilter and PCL NPs incorporated CA biofilter. (b) Water flux for Bovine Serum 
Albumin (BSA,●), Ovalbumin (■), Bovine Hemoglobin (▲), Lysozyme (○) and  
Trastuzumab (TTZ, □) spiked endotoxin solution in water though CA (dotted lines) and 
PCL incorporated CA biofilter (solid lines). Protein and endotoxin concentration during 
the experiments were kept constant at 1000 g/ml and 57.4 g/ml. CA (open shape; 
dotted line) and PCL incorporated CA biofilter (Solid shape; solid line). 
At the end of 90 minutes the average removal efficiency values varied from 75 % 
(4.3 × 10ହ  EU/ml) for TTZ to 92% (5.3 × 10ହ  EU/ml) for BSA (Figure. 8a and S8). In 
terms of protein recovery, the values varied from 92 % for ovalbumin to 100 % for BSA 
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and TTZ at the end of 15 minutes (Figure. 8b). At the end of 90 minutes duration the 
recovery values varied between 98 and 100 % for all proteins under consideration 
(Figure. 8b). The high recovery values suggest that there is minimal non-specific binding 
between the protein and the PCL NPs located in the CA biofilter. For blank CA biofilter 
without PCL NPs, at the end of 15 minutes the endotoxin removal values were low and 
varied between 6% (3.4 × 10ସ  EU/ml)  and 30 % (1.7 × 10ହ  EU/ml) (Figure. 8a and 
S8). After 90 minutes, the endotoxin removal varied between 0 and 25 % (1.4 × 10ହ  




Figure 8. The endotoxin removal efficiency and protein recovery of different proteins 
using CA and PCL incorporated CA biofilter. (a) Endotoxin removal efficiency from 
Bovine Serum Albumin (BSA,●), Ovalbumin (■), Bovine Hemoglobin (▲), Lysozyme 
(○) and  Trastuzumab (TTZ, □) spiked endotoxin solution in water using CA (dotted 
lines)  and PCL incorporated CA biofilter (solid lines). Protein and endotoxin 
concentration during the experiments were kept constant at 1000 g/ml and 57.4 g/ml. 
(b) Protein recovery for Bovine Serum Albumin (BSA,●), Ovalbumin (■), Bovine 
Hemoglobin (▲), Lysozyme (○) and  Trastuzumab (TTZ, □) spiked endotoxin solution in 
water using CA and PCL incorporated CA biofilter. Protein concentration during the 





Figure 8. The endotoxin removal efficiency and protein recovery of different proteins 
using CA and PCL incorporated CA biofilter. (a) Endotoxin removal efficiency from 
Bovine Serum Albumin (BSA,●), Ovalbumin (■), Bovine Hemoglobin (▲), Lysozyme 
(○) and  Trastuzumab (TTZ, □) spiked endotoxin solution in water using CA (dotted 
lines)  and PCL incorporated CA biofilter (solid lines). Protein and endotoxin 
concentration during the experiments were kept constant at 1000 g/ml and 57.4 g/ml. 
(b) Protein recovery for Bovine Serum Albumin (BSA,●), Ovalbumin (■), Bovine 
Hemoglobin (▲), Lysozyme (○) and  Trastuzumab (TTZ, □) spiked endotoxin solution in 
water using CA and PCL incorporated CA biofilter. Protein concentration during the 




In this work, bare PCL NPs (~ 800 nm) were synthesized using the solvent 
evaporation technique.[21] PCL NPs were effective in binding endotoxins from biological 
solutions thus decontaminating the solution for parenteral application. To begin with, the 
effect of different pH conditions on protein recovery using PCL NPs was investigated. 
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For the experiments, three types of pH conditions were considered: pH 2.8 (acidic), pH = 
pI (isoelectric point of protein) and pH 11.5 (basic). Isoelectric points of PCL used in the 
experiments was at pH 4 and for that of endotoxin was at pH 2.[3, 8, 42] Thus, at any pH < 
4, PCL would be positively charged and negatively charged at any pH > 4. Similarly, at 
any pH < 2, endotoxins would be positively charged and negatively charged at any pH > 
2. Isoelectric points for proteins investigated are: Ovalbumin (pI 4.5), BSA (pI 4.7), 
fibrinogen (pI 5.8), bovine hemoglobin (pI 7.1), TTZ (pI 8.5) and lysozyme (pI 10.7). At 
pH 2.8, all the proteins and PCL NPs surface would possess a positive charge and 
endotoxin would be negatively charged. Protein recovery varied between 93 and 100 
%.Van der Waals, hydrophobic and ionic interaction would be responsible for endotoxin 
binding on PCL surface. PCL and proteins have same type of charges thus ionic 
interaction would not cause any protein binding on PCL surface. Hence, the loss of 
protein would be due to protein binding on endotoxin surface due to ionic, affinity and 
hydrophobic interaction.[3, 8, 43]  Subsequently, the protein laden endotoxin binds to the 
PCL surface. Also, possibility of interaction between the PCL surface and proteins cannot 
be neglected. In the past, lysozyme and hemoglobin have been reported to show strong 
interaction with endotoxin thus corroborating the possibility of interaction between 
proteins and endotoxins.[3, 8, 43] At isoelectric point, the surface of proteins are neutral, 
both endotoxins and PCL NPs possess a negative charge due to their phosphate and 
carbonyl groups respectively. Protein recovery varied between 98 and 100 % thus 
indicating almost no interaction either between the protein and the PCL NPs or the 
protein and the endotoxin. At pH 11.5, the surface of proteins, PCL NPs and endotoxins 
possess a negative charge respectively. Protein recovery varies between 94 and 100 %. 
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Due to similar charges on all the surfaces, ionic interaction would not contribute towards 
any loss in protein after endotoxin removal. Hence, the loss in protein would be due to 
affinity, van der Waals and hydrophobic interaction between PCL surface and proteins or 
endotoxin and proteins.[3, 8, 43] To sum up, pH does play a role in protein recovery but in 
almost all cases the protein recovery was > 93 % which is considered reasonably high. 
Further, PCL NPs binding experiments were carried out by suspending PCL NPs 
in the endotoxin spiked solution and then centrifuged to separate out the endotoxin laden 
PCL NPs from the solution. From literature, it has been suggested that the synergistic 
combination of van der Waals and hydrophobic interaction are driving the binding of 
endotoxin on PCL NPs surface.[21] 
The aim of this paper was to test the validity of the hypothesis.  To begin with 
polystyrene nanoparticles (PS NPs) of 𝑑௉~ 800 𝑛𝑚 with hydrophobic nature similar to 
that of PCL NPs were taken as a control. Subsequently, the endotoxin binding 
experiments were carried out to evaluate PS NPs endotoxin removal efficiency. PS NPs 
had an endotoxin removal efficiency of ~ 31 % (4.6 × 10ହ  EU/ml) in water (Figures. 3 
and S5; Table S2). The binding efficiency increased to 75 % (1.1 × 10଺  EU/ml) in PBS 
(Figures. 3 and S5; Table S2). Unlike PCL NPs, PS NPs endotoxin binding performance 
was not very impressive. These results suggests that endotoxin binding on the surface of 
PCL NPs is not solely due to van der Waals and hydrophobic interaction but there are 
other forces that are contributing towards the endotoxin adsorption on PCL surface and 
need further investigation. Even though, van der Waals and hydrophobic forces are 
contributing towards endotoxin binding but that is just a small part of large group of 
forces as evident from low removal efficiency by PS’s hydrophobic surface.  
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The presence of water and salt molecules also play an important role in 
strengthening the binding interaction between endotoxin and PCL molecules. Endotoxin 
structure comprises a negative charge due to the presence of phosphate group (PO43-) in 
its polar head chain. On the other hand, PCL NPs also possess negative charge due to the 
carbonyl group (CO-) in its structure. The presence of negative charges on both the 
surfaces should have induced a strong electrostatic repulsive action and thus should have 
acted as a barrier and impeded the binding on endotoxin on PCL surface. However, the 
presence of water and salt (NaCl) molecules result in ion hydration through H+ and Na+ 
ions and thus stabilize the charged surfaces (endotoxin and PCL) and strengthen the 
attractive binding forces between endotoxin and PCL NPs surface.[21, 44, 45]     
Study was also carried out to evaluate the endotoxin binding efficiency due to 
ionic interaction. This was done  by coating the surface of the PCL NPs with three 
different cationic ligands, PLL, PEI and chitosan to make the surface cationic.[33] 
Subsequently, after coating the PCL NPs with the cationic ligands the zeta potential 
(surface charge) of the particles increased from ~ -17 mV (Figure. 1c) to 8, 12.6 and  1.4 
mV (Figures. 3b, 3c and 3d) confirming the surface modification. The % conjugation 
efficiency of the three ligands on PCL surface varied between 60 and 70 %. (Figure. 3a). 
On comparing the endotoxin removal efficiency of the bare PCL NPs with the positively 
charged cationic NPs in water, it was observed that PCL NPs possessed a much higher ~ 
82 % (1.2 × 10଺ EU/ml) endotoxin removal efficiency than modified NPs with values 
varying between 10 and 32 % (1.5 × 10ହ − 5 × 10ହ  EU/ml) (Figures. 4 and S5; Table 
S2). In presence of PBS the endotoxin binding efficiency of modified cationic NPs 
reduced further to ~ 8-10 % (1.2 × 10ହ − 1.4 × 10ହ EU/ml) (Figures. 4 and S5; Table 
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S3). Thus, suggesting that in case of binding due to ionic interaction taking place in 
water, salt ions are used to modulate the binding capacity.[46] The role of positively 
charged NPs is to bind endotoxin through its negatively charged phosphate group in 
water but in presence of salt (NaCl; 137 mM) in PBS, charge shielding effect comes into 
play as in addition to negatively charged endotoxin molecules, chloride ions are also 
competing for the same binding site thus reducing the particle’s endotoxin binding 
efficiency even further.[46-49]  Even though, porous resins or particle based 
chromatographic separation techniques were quite mature and effective but they suffered 
from various limitations like poor mass transfer, high pressure drop and in some cases 
low purification efficiency as seen in the case of polymyxin B cross-linked cellulose 
microspheres.[25, 26, 50, 51] The porous microspheres ~ 150 µm in size possessed high 
endotoxin binding capacity of ~ 3.6 × 10଺ EU/mg but suffered from poor mass transfer 
and large pressure drop.[51] To address these drawbacks the non-porous particle (PCL 
NPs) loaded biofilter were synthesized which combined the advantages of high binding 
capacity of the particles with improved flow properties and reduced pressure drop of the 
flat-sheet filter.[21, 25, 26] From literature, it has been shown that PCL NPs (~ 800 nm) 
incorporated CA biofilter were effective in removing endotoxins from water.[21] Here we 
applied that biofilter to protein solutions and demonstrated the effectiveness of the 
biofilter in removing endotoxin from protein solutions. Non-porous PCL NPs (~ 800 nm) 
with a BET specific area of ≈ 6.5 𝑚ଶ/𝑔  are very effective in removing endotoxins from 
water, biological and protein solutions.[21] Hence, on incorporating these in the biofilter 
matrix the combined advantages of both the particles and filters can be utilized for cost 
effective and efficient downstream purification with higher throughput. [25]  
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Non-porous PCL NPs loaded biofilter used in the experiments were fed with five 
types of endotoxin spiked proteins, namely, ovalbumin, BSA, bovine hemoglobin, TTZ 
and lysozyme. The biofilter possessed a high maximum endotoxin removal efficiency 
varying between 95 and 99 % (TTZ-ovalbumin;5.5 × 10ହ − 5.7 × 10ହ )(Figure. 8a and 
S8 ).Thus suggesting that PCL NPs loaded biofilter were quite effective in providing 
binding sites for removing endotoxin from protein solutions. In addition to the high 
endotoxin removal efficiency the protein recovery after endotoxin removal varied 
between 92 and 100 % (Figure. 8b) , thus suggesting that the majority of binding sites 
within the biofilter were being utilized for endotoxin binding and most of the protein was 
allowed to pass through. In comparison, CA biofilter without any PCL NPs showed low 
endotoxin removal efficiency between 0 % and 30 %. Another advantage associated with 
the biofilter was the flux at which the removal took place. PCL NPs loaded CA biofilter 
possessed a maximum pure water flux of ~ 150 ௅
௠మ.௛
  (Figure. 7a) and an average protein 
and endotoxin spiked water flux of ~ 41 ௅
௠మ.௛
 , thus highlighting the rapidness of the 
separation (Figure. 7b). It is worth mentioning here that the CA biofilter used for the 
endotoxin removal from protein solutions were gravity driven (Figure. S7) thus cutting 




In this work, the goal was to test the validity of the hypothesis that endotoxin 
binding on PCL NP surface was due to van der Waals and hydrophobic interaction 
occurring between lipid-A tail of endotoxins and hydrophobic surface of PCL. This was 
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evaluated by taking polystyrene nanoparticles, which have similar hydrophobic nature as 
polycaprolactone nanoparticles used as control. Subsequently, PS NPs did not show as 
high endotoxin removal (31%-75 %) efficiency as PCL NPs thus suggesting that in case 
of PCL NPs there were attractive forces other than van der Waals and hydrophobic 
interaction that  resulted in high endotoxin binding efficiency and need further 
investigation.  Further, the effect of pH on protein recovery for PCL NPs were also 
evaluated. Six different types of proteins with molecular weights varying from 14 kDa 
- 341 kDa and isoelectric points (pI) from 4.5- 10.7 were selected. pH values of 2.8, 
isoelectric point of protein and 11.5 were selected for the experiments and it was 
observed that protein recovery irrespective of conditions were > 93 %, which is 
reasonably high. Thus suggesting that pH does not have a major effect on protein 
recovery when using PCL NPs. It has also been shown that PCL NPs incorporated CA 
biofilter are effective in removing endotoxins from various protein solutions with 
improved flow properties and higher throughput. The maximum endotoxin removal 
efficiency was ~ 99 % and a protein recovery > 92 % thus indicating that majority of 
endotoxin binding sites within the biofilter were being utilized for endotoxin binding and 
very less amount of protein was getting lost during the purification operation. 
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Table S1. Buffer recipes of different pHs to study the effects of pH on  




Figure S1. Protein standard curves of Ovalbumin, Bovine Serum Albumin (BSA), Fibrinogen, 
Bovine Hemoglobin, Trastuzumab (TTZ; Genentech) and Lysozyme at isoelectric points (pI) 





Figure S2. Protein standard curves of Ovalbumin, Bovine Serum Albumin (BSA), 
Fibrinogen, Bovine Hemoglobin, Trastuzumab (TTZ; Genentech) and Lysozyme at pH 




Figure S3. Protein standard curves of Ovalbumin, Bovine Serum Albumin (BSA), 
Fibrinogen, Bovine Hemoglobin, Trastuzumab (TTZ; Genentech) and Lysozyme at pH 




Figure S4. Poly-L-Lysine (PLL), Polyethylenimine (PEI) and chitosan standard curves 
for conjugation efficiency calculation using ninhydrin assay. The curves were used to 
measure the ligand concentrations. R2 represents the regression value. 
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Table S2. The endotoxin unit (EU) bound per ml of endotoxin-spiked solution using PCL 
NPs and Polystyrene (PS) NPs in water and PBS at different dilutions. 1 EU≈




Figure S5. Comparison of Endotoxin unit (EU) per ml bound to the surface of PCL NPs 
with Polystyrene NPs (𝑑௉~ 800 𝑛𝑚) in water and PBS at different dilutions. EU/ml fed 
was kept constant at 1.5 × 106 and particle concentration at 1000 g/ml. * indicates the p-
value < 0.1 showing a statistically significant difference between % endotoxin removal in 
water and PBS. 
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Table S3. The endotoxin unit (EU) bound per ml of endotoxin-spiked solution using PCL 
NPs and modified PCL NPs in water. 1 EU≈ 0.1 – 0.2 𝑛𝑔 of endotoxin. 
 
Table S4. The endotoxin unit (EU) bound per ml of endotoxin-spiked solution using PCL 







Figure S6. Endotoxin unit (EU) per ml bound to the surface of PCL NPs, PLL, PEI and 
chitosan coated PCL NPs in RO water and PBS. EU/ml fed was kept constant at 1.5 × 106 
and particle concentration at 1000 g/ml. ***, ** and * indicates the p-value < 0.01, < 
0.05 and < 0.1 showing a statistically significant difference between % endotoxin 
removal in water and PBS. 
  
146
Figure S7. Custom-made membrane filtration set up made out of PVC. CA biofilter 
without and with PCL NPs are sandwiched between two blocks and butterfly screws are 
used to tighten the biofilter. Endotoxin spiked protein solution is fed from the top part of 




























Figure S8. Endotoxin units (EU) per ml removed from Bovine Serum Albumin (BSA,●), 
Ovalbumin (■), Bovine Hemoglobin (▲), Lysozyme (○) and  Trastuzumab (TTZ, □) 
spiked endotoxin solution in water using PCL incorporated CA biofilter (solid lines). 
Protein and endotoxin concentration during the experiments were kept constant at 1000 
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2. CONCLUSIONS AND FUTURE WORK 
2.1. CONCLUSIONS  
In paper-I, we reported the synthesis of polymeric PCL NPs by employing a 
solvent evaporation method, followed by the performance evaluation of PCL NPs for the 
adsorption and removal of  endotoxins. It was found that PCL NPs in powder form 
removed around 88% of endotoxins from the water sample. The presence of salts, by 
adding PBS, increased the endotoxin removal efficiency further up to 100 % while 
maintaining 100% protein recovery from solutions. Such high removal efficiency of 
endotoxin from water and PBS is attributed to strong hydrophobic and van der Waals 
interactions. Buffers of variable pH play a very important role in determining the 
endotoxin binding on PCL. Acidic (pH 2.8) and alkaline (pH 9.6) buffers give ~ 90% 
endotoxin removal whereas intermediate pHs from 5.8 to 8 give reasonably lower % 
endotoxin removal, that is, between 30 and 75%.  The adsorption efficiency reached 
almost 100% when PCL NPs were incorporated into the CA membrane where the water 
flow through the porous structure was directly facilitated by gravity (not requiring any 
pumping devices). The biocompatible PCL NPs can be reused by desorbing majority of 
adsorbed endotoxin using 0.2 N NaOH solution.  A preliminary cost analysis showed that 
the manufacturing cost of the PCL NP-embedded CA membrane is quite affordable.  
These findings, coupled with PCL NP’s known biodegradability, support the potential of 
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hybrid NP-membrane system use in large-scale operations that remove endotoxins 
efficiently and reduce the downstream process costs in biotechnological industries. 
In paper-II, the goal was to test the validity of the hypothesis that endotoxin 
binding on PCL NP surface was due to van der Waals and hydrophobic interaction 
occurring between lipid-A tail of endotoxins and hydrophobic surface of PCL. This was 
evaluated by taking polystyrene nanoparticles, which have similar hydrophobic nature as 
polycaprolactone nanoparticles used as control. Subsequently, PS NPs did not show as 
high endotoxin removal (31%-75 %) efficiency as PCL NPs thus suggesting that in case 
of PCL NPs there were attractive forces other than van der Waals and hydrophobic 
interaction that  resulted in high endotoxin binding efficiency and need further 
investigation.  Further, the effect of pH on protein recovery for PCL NPs were also 
evaluated. Six different types of proteins with molecular weights varying from 14 kDa 
- 341 kDa and isoelectric points (pI) from 4.5- 10.7 were selected. pH values of 2.8, 
isoelectric point of protein and 11.5 were selected for the experiments and it was 
observed that protein recovery irrespective of conditions were > 93 %, which is 
reasonably high. Thus suggesting that pH does not have a major effect on protein 
recovery when using PCL NPs. It has also been shown that PCL NPs incorporated CA 
biofilter are effective in removing endotoxins from various protein solutions with 
improved flow properties and higher throughput. The maximum endotoxin removal 
efficiency was ~ 99 % and a protein recovery > 92 % thus indicating that majority of 
endotoxin binding sites within the biofilter were being utilized for endotoxin binding and 
very less amount of protein was getting lost during the purification operation. 
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2.2. FUTURE WORK 
1. Expanding the application of PCL NPs loaded cellulose acetate (CA) biofilter for 
removal of harmful algal toxins from lake waters. To begin with our target toxins 
will be cyanotoxins, eg: anatoxin and microcystin-LR which are found quite 
extensively in the lake water.    
2. Exploring the possibility of using BODIPY dye, which is a lipid biomarker as a 
toxin detection kit at different toxin concentrations, operating conditions and in 
different solutions. BODIPY has already been shown to detect endotoxins 
successfully as the structure of endotoxin molecules comprises of non-polar lipid-
A molecules in its tail part which is hydrophobic in nature. BODIPY, which is 
fluorescent dye shows this unique property of quenching in its fluorescence 
intensity when it comes in contact with lipid molecules. Thus, this quenching 
property of BODIPY on coming in contact with lipid molecules was utilized to 
come up with a detection kit for endotoxins. Quantification of endotoxin was 
done by measuring the drop in fluorescence intensity (quenching) using the 
optical microplate reader. Our future work will comprise of testing the minimum 
endotoxin detection limit of BODIPY dye and also investigate the different algal 
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